Compositions and methods of use for treating 12-lipoxygenase (12-LOX) mediated diseases
By developing a compound of formula (I) that specifically binds to 12-LOX, the problem of increased bleeding risk from existing antiplatelet drugs has been solved, achieving effective treatment of HIT and T1D and reducing cardiovascular events.
Patent Information
- Application Number
- CN202280091208.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-10-27
- Filing Date
- 2022-12-16
- Publication Date
- 2024-11-22
AI Technical Summary
Existing antiplatelet drugs increase the risk of unnecessary bleeding when inhibiting platelet function, and there is a lack of effective treatments for 12-lipoxygenase (12-LOX) mediated diseases such as heparin-induced thrombocytopenia (HIT) and type 1 diabetes (T1D).
A compound of formula (I) and its pharmaceutically acceptable salt were developed that modulates platelet function by specifically binding to 12-LOX, reducing unwanted platelet activation and aggregation, and lowering the risk of bleeding.
It effectively treats 12-LOX-mediated diseases such as HIT and T1D, reduces platelet activation and aggregation, lowers the risk of cardiovascular events, and reduces the risk of bleeding.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_5
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This patent application is an international patent application claiming priority to U.S. Provisional Application No. 63 / 381,191 filed on October 27, 2022, U.S. Provisional Application No. 63 / 390,380 filed on July 19, 2022, U.S. Provisional Application No. 63 / 338,111 filed on May 4, 2022, and U.S. Provisional Application No. 63 / 293,132 filed on December 23, 2021, the disclosure of each of which is incorporated herein in its entirety for all purposes. Technical Field
[0003] The present disclosure provides compounds, compositions comprising them, and pharmaceutical uses thereof, such as compositions suitable for treating diseases mediated by 12-lipoxygenase (12-LOX). The present disclosure further provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treating, for example, heparin-induced thrombocytopenia (HIT) and type 1 diabetes (T1D). Background Art
[0004] Regulation of platelet function is essential for the prevention and treatment of cardiovascular atherosclerotic events such as coronary artery disease and stroke. Although current antiplatelet drugs can effectively inhibit platelet function and prevent thrombotic complications, these treatments often increase the risk of unnecessary bleeding. Therefore, there is an unmet need to identify new antiplatelet targets that can prevent unnecessary platelet activation under disease conditions and reverse platelet inhibition with minimal bleeding risk. Platelet adhesion and aggregation at sites of vascular injury are essential for maintaining normal hemostasis and preventing blood loss. However, when atherosclerotic plaque ruptures and compromises the integrity of the vessel wall, the same process can also lead to arterial thrombosis and vascular occlusion. Excessive platelet activation and aggregation can lead to the formation of occlusive thrombi and cause serious consequences, such as myocardial infarction, ischemic stroke and pulmonary embolism, which are the main causes of morbidity and mortality worldwide. Antiplatelet therapy is considered the gold standard for its effective prevention of abnormal platelet activation and is essential in treating cardiovascular atherosclerotic events to reduce morbidity and mortality. Currently approved antiplatelet therapies inhibit platelet function by targeting platelet enzymes, receptors, and glycoproteins. Although these treatments limit platelet function, they often result in an increased risk of bleeding. Therefore, there is a need to identify novel antiplatelet therapeutic targets that limit bleeding.
[0005] 12-Lipoxygenase (12-LOX) is an enzyme that oxidizes fatty acids, produces pro-inflammatory metabolites, and is associated with a variety of diseases, including heparin-induced thrombocytopenia (HIT) and type 1 diabetes (T1D). Therefore, there is a need to develop therapeutics for these diseases. Summary of the invention
[0006] The present invention provides a compound of formula (I)
[0007]
[0008] or a pharmaceutically acceptable salt thereof, wherein Z is
[0009]
[0010] And among them
[0011] R1 is hydrogen or optionally substituted cycloalkyl, aryl or C1-C3 alkylaryl, each of which is optionally substituted with one or more substituents independently selected from halogen, alkyl, haloalkyl, alkoxy, C1-C3 haloalkoxy or heterocycle;
[0012] R2 is selected from H, halogen, deuterium, alkyl, haloalkyl, C1-C3 alkoxy and C1-C3 haloalkoxy, hydroxyalkyl, alkoxyalkyl, cycloalkyl including cyclopropyl, C1-C3
[0013] Alkyl aryl, or including Substituted or unsubstituted aryl and aralkyl, or including Amides of, wherein R9 is independently selected from C1-C3 alkyl, cycloalkyl (including cyclopropyl) and substituted or unsubstituted phenyl;
[0014] or R1 and R2 together with the thiazole ring form an optionally substituted 5-, 6- or 7-membered fused 1,2-carbocyclic ring system, wherein the ring carbons of the 5-, 6- or 7-membered fused ring are optionally substituted with one or more atoms selected from N, O and S. The fused 5-, 6- or 7-membered ring is optionally substituted independently with one or more halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, or an optionally substituted aromatic ring;
[0015] Or R1 and R2 together with the carbon to which they are attached form a substituted or unsubstituted
[0016]
[0017] R3 is hydrogen, C1-C3 alkyl or C1-C3 haloalkyl;
[0018] Each R4 is independently hydrogen, CD3, substituted or unsubstituted phenyl, cycloalkyl including cyclopropyl, C1-C3 alkyl, C1-C3 haloalkyl, -OR, C1-C3 haloalkoxy or halogen;
[0019] R5 is hydrogen, C1-C3 alkyl or C1-C3 haloalkyl;
[0020] R6 is hydrogen, CD3, alkyl, cycloalkyl, haloalkyl or
[0021]
[0022] Each R7 is independently hydrogen, alkyl, haloalkyl, cycloalkyl or halogen;
[0023] R8 is hydrogen, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;
[0024] n is 0, 1 or 2;
[0025] p is 0, 1, 2 or 3;
[0026] or a pharmaceutically acceptable salt, prodrug, solvate, hydrate or stereoisomer thereof. DETAILED DESCRIPTION
[0027] 1. General description of certain embodiments of the present invention:
[0028] In one aspect, the present invention provides a compound of formula (I')
[0029]
[0030] or a pharmaceutically acceptable salt thereof, wherein:
[0031] Ring Z' is an optionally substituted 5- to 6-membered monocyclic aromatic or heteroaromatic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen or sulfur. One or more optional substitutions in ring Z' include independently replacing one or more hydrogen atoms in the CH bonds of the ring with one or more of the following: halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR 10 , -N(R)2, or
[0032]
[0033] Where R 10 are independently hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Cycloalkyl, C 1-6 Halogenated cycloalkyl, phenyl.
[0034] L1 is a covalent bond or C 1-6A divalent straight or branched hydrocarbon chain, wherein one or two methylene units of the chain are independently and optionally substituted by: -OC(O)-, -C(O)O-, -OC(O)-, -N(R 11 )-、-C(O)N(R 11 )-、-(R 11 )NC(O)-、-OC(O)N(R 11 )-、-(R 11 )NC(O)O-、-N(R 11 )C(O)N(R 11 )-, -S-, -SO-, -SO2-, -SO2N(R 11 )-、-(R 11 )NSO2-, -C(S)-, -C(S)O-, -OC(S)-, -C(S)N(R 11 )-、-(R 11 )NC(S)-or-(R 11 )NC(S)N(R 11 )-; where R 11 is independently hydrogen or an optionally substituted group selected from: C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Cycloalkyl, or C 1-6 halocycloalkyl, or an optionally substituted group selected from the following: C 1-6 aliphatic, a 3- to 8-membered saturated or partially unsaturated monocyclic carbocycle, phenyl, an 8- to 10-membered bicyclic aromatic carbocycle, a 4- to 8-membered saturated or partially unsaturated monocyclic heterocycle having 1 to 2 heteroatoms independently selected from nitrogen, oxygen or sulfur, a 5- to 6-membered monocyclic heteroaromatic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or an 8- to 10-membered bicyclic heteroaromatic ring having 1 to 5 heteroatoms independently selected from nitrogen, oxygen or sulfur.
[0035] In some embodiments, the present invention provides a compound of formula (I)
[0036]
[0037] or a pharmaceutically acceptable salt thereof, wherein Z is
[0038]
[0039] And among them
[0040] R1 is hydrogen or optionally substituted cycloalkyl, aryl or C1-C3 alkylaryl, each of which is substituted by one or more substituents independently selected from halogen, alkyl, haloalkyl, alkoxy, C1-C3 haloalkoxy and heterocycle;
[0041] R2 is selected from H, halogen, deuterium, alkyl, haloalkyl, C1-C3 alkoxy and C1-C3 haloalkoxy, hydroxyalkyl, alkoxyalkyl, cycloalkyl including cyclopropyl, C1-C3 alkylaryl, or Substituted or unsubstituted aryl and aralkyl, or including Amides of, wherein R9 is independently selected from C1-C3 alkyl, cycloalkyl (including cyclopropyl) and substituted or unsubstituted phenyl;
[0042] or R1 and R2 together with the thiazole ring form an optionally substituted 5-, 6- or 7-membered fused 1,2-carbocyclic ring system, wherein the ring carbons of the 5-, 6- or 7-membered fused ring are optionally substituted with one or more atoms selected from N, O and S. The fused 5-, 6- or 7-membered ring is optionally substituted independently with one or more halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, or an optionally substituted aromatic ring;
[0043] Or R1 and R2 together with the carbon to which they are attached form a substituted or unsubstituted or substituted
[0044]
[0045] R3 is hydrogen, C1-C3 alkyl or C1-C3 haloalkyl;
[0046] Each R4 is independently hydrogen, C1-C3, substituted or unsubstituted phenyl, cycloalkyl including cyclopropyl, halogen, C1-C3 alkyl, C1-C3 alkylaryl, C1-C3 haloalkyl, C1-C3 alkoxy or C1-C3 haloalkoxy;
[0047] R5 is hydrogen, C1-C3 alkyl or C1-C3 haloalkyl;
[0048] R6 is hydrogen, CD3, alkyl, cycloalkyl, haloalkyl or
[0049]
[0050] Each R7 is independently hydrogen, haloalkyl, haloalkyl or cycloalkyl;
[0051] R8 is hydrogen, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;
[0052] n is 0, 1 or 2;
[0053] p is 0, 1, 2 or 3;
[0054] or a pharmaceutically acceptable salt, prodrug, solvate, hydrate or stereoisomer thereof.
[0055] Also described herein are methods of treating a disease in a patient susceptible to treatment with a disclosed compound by administering to the patient an effective amount of a disclosed compound.
[0056] Also described herein are methods of treating a disease or condition by administering to a patient in need thereof an effective amount of a disclosed compound.
[0057] The present disclosure also includes pharmaceutical compositions comprising an effective amount of the disclosed compounds and a pharmaceutically acceptable carrier. The compositions can be used to treat or prevent a disease or condition. The present disclosure includes the disclosed compounds provided as pharmaceutically acceptable prodrugs, hydrates, salts, stereoisomers, or mixtures thereof.
[0058] The details of the present disclosure are set forth in the following attached description. Although methods and materials similar to or equivalent to those described herein can be used for the practice or testing of the present disclosure, illustrative methods and materials will now be described. According to this specification and claims, other features, purposes and advantages of this description will become apparent. In the specification and the appended claims, unless the context clearly specifies otherwise, the singular form also includes the plural form. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those of ordinary skill in the art to which the present invention belongs, or all technical and scientific terms used herein have the same meanings as those of ordinary skill in the art to which the present disclosure belongs, which are generally understood. All patents and publications cited in this specification are incorporated herein by reference in their entirety.
[0059] 2. Compounds and Definitions:
[0060] The compounds of the present invention are included in the compounds generally described herein, and are further illustrated by the categories, subclasses and species disclosed herein. As used herein, unless otherwise indicated, the following definitions shall apply. For purposes of the present invention, chemical elements are identified according to the periodic table, CAS version, chemistry and physics handbook 75th edition. In addition, the general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999 and "March's Advanced Organic Chemistry", 5th edition, editors: Smith, MB and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are incorporated herein by reference.
[0061] The articles "a" and "an" are used in this disclosure to refer to one or to more than one (ie, to at least one) of the grammatical object of the article. As an example, "an element" means one element or more than one element.
[0062] Unless stated otherwise, the term "and / or" is used in this disclosure to mean "and" or "or".
[0063] As used herein, the term "unsaturated" means a moiety having one or more units of unsaturation.
[0064] As used herein, the term "divalent C 1至n A "saturated or unsaturated straight or branched hydrocarbon chain" refers to straight or branched divalent alkylene, alkenylene and alkynylene chains as defined herein.
[0065] As used herein, the term "aliphatic" or "aliphatic group" means a straight chain (i.e., unbranched) or branched substituted or unsubstituted hydrocarbon chain that is completely saturated or contains one or more unsaturated units, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or contains one or more unsaturated units but is not aromatic, and has a single point of connection with the rest of the molecule. Unless otherwise specified, an aliphatic group contains 1 to 6 aliphatic carbon atoms. In some embodiments, an aliphatic group contains 1 to 5 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1 to 4 aliphatic carbon atoms. In still other embodiments, an aliphatic group contains 1 to 3 aliphatic carbon atoms, and in yet other embodiments, an aliphatic group contains 1 to 2 aliphatic carbon atoms. In some embodiments, "cycloaliphatic" (or "carbocycle" or "cycloalkyl") refers to a monocyclic C3-C6 hydrocarbon that is saturated or contains one or more unsaturated units but is not aromatic, and has a single point of connection with the rest of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and mixtures thereof, such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
[0066] As used herein, the term "hydrogen" when referring to an atomic substituent means a covalent hydrogen atom, e.g. H 2O, -C H 3. -N H 2. -O H , (methyl group) or C H 4. It does not refer to diatomic hydrogen (H2).
[0067] The term "alkylene" refers to a divalent alkyl group. An "alkylene chain" is a polymethylene group, i.e., -(CH2) n-, wherein n is a positive integer, preferably 1 to 6, 1 to 4, 1 to 3, 1 to 2 or 2 to 3. Substituted alkylene chains are polymethylene groups in which one or more methylene hydrogen atoms are replaced by substituents. Suitable substituents include the substituents described below for substituted aliphatic groups.
[0068] The term "alkenylene" refers to a divalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced by a substituent. Suitable substituents include those described below for substituted aliphatic groups.
[0069] As used herein, the term "cyclopropenyl" refers to a divalent cyclopropyl radical having the following structure:
[0070] The term "halogen" or "halo" refers to a covalently bonded halogen atom, such as -F, -Cl, -Br or -I. The term "fluorine" as used herein refers to a covalently bonded fluorine atom, such as C F 3CO2H, -C F 3. Unless otherwise specified, it does not refer to diatomic fluorine gas (F2). As used herein, this also applies to chlorine, bromine and iodine.
[0071] The term "aryl", used alone or as part of a larger moiety such as in "aralkyl", "aralkyloxy" or "aryloxyalkyl", refers to a monocyclic or bicyclic ring system having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term "aryl" can be used interchangeably with the term "aromatic ring". In certain embodiments of the present invention, "aryl" refers to an aromatic ring system including but not limited to phenyl, biphenyl, naphthyl, anthracenyl, etc., which may carry one or more substituents. As used herein, the term "aryl" also includes within its scope groups in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthalimidyl, phenanthridinyl or tetrahydronaphthyl, etc.
[0072] The terms "heteroaryl" and "heteroar-", used alone or as part of a larger moiety such as "heteroaralkyl" or "heteroaralkoxy", refer to groups having 5 to 10 ring atoms, preferably 5, 6 or 9 ring atoms; sharing 6, 10 or 14 pi electrons in a cyclic array; and having 1 to 5 heteroatoms in addition to carbon atoms. The term "heteroatom" refers to nitrogen, oxygen or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. Heteroaryl includes, but is not limited to, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl and pteridinyl. As used herein, the terms "heteroaryl" and "heteroaryl-" also include groups in which a heteroaromatic ring is fused to one or more aryl, alicyclic or heterocyclic rings, wherein the group or point of attachment is located on the heteroaromatic ring. Non-limiting examples include: indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzothiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolyl, tetrahydroisoquinolyl and pyrido [2,3-b] -1,4-oxazine-3 (4H) -one. The heteroaryl group can be monocyclic or bicyclic. The term "heteroaryl" may be used interchangeably with the terms "heteroaryl ring," "heteroaryl group," or "heteroaromatic," any of which includes optionally substituted rings. The term "heteroaralkyl" refers to an alkyl substituted with a heteroaryl, wherein the alkyl and heteroaryl portions are independently optionally substituted.
[0073] As used herein, the terms "heterocycle", "heterocyclyl", "heterocyclic radical" and "heterocyclic ring" are used interchangeably and refer to a stable 5- to 7-membered monocyclic, or 7- to 10-membered bicyclic polycyclic heterocyclic moiety that is saturated or partially unsaturated and has one or more (preferably one to four) heteroatoms in addition to carbon atoms, as defined above. When used with respect to a ring atom of a heterocycle, the term "nitrogen" includes substituted nitrogen. For example, in a saturated or partially unsaturated ring having 0 to 3 heteroatoms selected from oxygen, sulfur or nitrogen, nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or + NR (as in N-substituted pyrrolidinyl).
[0074] The heterocycle can be connected to its side group at any heteroatom or carbon atom to produce a stable structure, and any ring atom can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic groups include, but are not limited to, tetrahydrofuranyl, tetrahydrophenylthio, pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolyl, tetrahydroisoquinolyl, decahydroquinolyl, oxazolidinyl, piperazinyl, dioxane-based, dioxolanyl, diazepine, oxazapine, thiazopine, morpholinyl and quinuclidinyl. The terms "heterocycle", "heterocyclyl", "heterocyclyl ring", "heterocyclic group", "heterocyclic moiety" and "heterocyclic group" are used interchangeably herein and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl or alicyclic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl or tetrahydroquinolinyl. The heterocyclyl group may be monocyclic or bicyclic. The term "heterocycloalkyl" refers to an alkyl group substituted with a heterocyclyl group, wherein the alkyl and heterocyclyl groups are independently optionally substituted.
[0075] As used herein, the term "partially unsaturated" refers to a ring moiety containing at least one double or triple bond. The term "partially unsaturated" is intended to encompass rings with multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as defined herein.
[0076] As described herein, the compounds of the present invention may contain "optionally substituted" moieties. In general, the term "substituted", whether preceded by or without the term "optionally", means that one or more hydrogens of the specified moiety are replaced by suitable substituents. Unless otherwise indicated, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted by more than one substituent selected from a specified group, the substituent may be the same or different at each position. The combinations of substituents contemplated by the present invention are preferably those that result in the formation of stable or chemically feasible compounds. The term "stable" as used herein refers to a compound that is substantially unchanged when subjected to conditions that allow its production, detection, and in certain embodiments, its recovery, purification, and use for one or more purposes disclosed herein.
[0077] Each optional substituent on a substitutable carbon is a monovalent substituent independently selected from the group consisting of: halogen; -(CH2); 0– 4R o ; –(CH2) 0–4 OR o ; -O(CH2) 0-4 R o 、–O–(CH2) 0–4 C(O)OR o ; –(CH2)0–4 CH(OR o )2; –(CH2) 0–4 SR o ; –(CH2) 0–4 Ph, which can be o Substitution; –(CH2) 0–4 O(CH2) 0–1 Ph, which can be o Substitution; –CH=CHPh, which can be replaced by R o Substitution; –(CH2) 0–4 O(CH2) 0–1 -pyridyl, which may be R o Substitution; –NO2; –CN; –N3; -(CH2) 0–4 N(R o )2; –(CH2) 0–4 N(R o )C(O)R o ; –N(R o )C(S)R o ; –(CH2) 0–4 N(R o )C(O)NR o 2;-N(R o )C(S)NR o 2; –(CH2) 0–4 N(R o )C(O)OR o ; –N(R o )N(R o )C(O)R o ;-N(R o )N(R o )C(O)NR o 2;-N(R o )N(R o )C(O)OR o ; –(CH2) 0–4 C(O)R o ; –C(S)R o ; –(CH2) 0–4 C(O)OR o ; –(CH2) 0–4 C(O)SR o ; -(CH2) 0–4 C(O)OSiR o 3; –(CH2) 0–4 OC(O)R o ; –OC(O)(CH2) 0– 4SR–、SC(S)SR o ; –(CH2)0–4 SC(O)R o ; –(CH2) 0–4 C(O)NR o 2; –C(S)NR o 2; –C(S)SR o ; –SC(S)SR o 、-(CH2) 0–4 OC(O)NR o 2; -C(O)N(OR o )R o ; –C(O)C(O)R o ; –C(O)CH2C(O)R o ; –C(NOR o )R o ; -(CH2) 0– 4SSR o ; -(CH2) 0–4 S(O)2R o ; –(CH2) 0–4 S(O)2OR o ; –(CH2) 0–4 OS(O)2R o ; –S(O)2NR o 2; -S(O)(NR o )R o ; –S(O)2N=C(NR o 2)2;-(CH2) 0–4 S(O)R o ;-N(R o )S(O)2NR o 2; –N(R o )S(O)2R o ;–N(OR o )R o ; –C(NH)NR o 2; –P(O)2R o ;-P(O)R o 2;-OP(O)R o 2;–OP(O)(OR o )2;SiR o 3;–(C 1–4 Straight or branched alkylene)O–N(R o )2; or – (C 1–4 Straight or branched alkylene) C(O)O–N(R o )2.
[0078] Each R o are independently hydrogen, C 1–6Aliphatic, –CH2Ph, –O(CH2) 0–1 Ph, -CH2-(5- to 6-membered heteroaryl ring), or a 5- to 6-membered saturated, partially unsaturated or aryl ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or, notwithstanding the above definitions, two independent occurrences of R o Together with its intervening atoms, it forms a 3- to 12-membered saturated, partially unsaturated or aromatic monocyclic or bicyclic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen or sulfur, which may be in R o The saturated carbon atom of o Optionally substituted with monovalent substituents independently selected from: halogen, –(CH2) 0–2 R · 、–(halogenated R · ),–(CH2) 0–2 OH, –(CH2) 0–2 OR · 、–(CH2) 0–2 CH(OR · )2; -O(halogenated R · )、–CN、–N3、–(CH2) 0–2 C(O)R · 、–(CH2) 0–2 C(O)OH, –(CH2) 0–2 C(O)OR · 、–(CH2) 0–2 SR · 、–(CH2) 0–2 SH, –(CH2) 0–2 NH2, –(CH2) 0–2 NHR · 、–(CH2) 0–2 NR · 2. –NO2, –SiR · 3. –OSiR · 3. -C(O)SR · ,–(C 1–4 Straight or branched alkylene)C(O)OR · or –SSR · .
[0079] Each R · Independently selected from C 1–4 Aliphatic, –CH2Ph, –O(CH2) 0–1 Ph, or a 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein each R ·is unsubstituted or, if preceded by halogen, substituted only with one or more halogens; or wherein the optional substituents on the saturated carbon are divalent substituents independently selected from the group consisting of: =O, =S, =NNR * 2. =NNHC(O)R * 、=NNHC(O)OR * 、=NNHS(O)2R * , =NR * , =NOR * , –O(C(R * 2)) 2–3 O–or–S(C(R * 2)) 2–3 S-, or the divalent substituent of the "optionally substituted" group bonded to the ortho-substitutable carbon is -O(CR * 2) 2–3 O–, where each independent occurrence of R * Selected from hydrogen, C 1–6 Aliphatic or unsubstituted 5- to 6-membered saturated, partially unsaturated or aryl ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen or sulfur.
[0080] When R * C 1-6 When aliphatic, R * Optionally halogen, –R · 、-(halogenated R · ), -OH, –OR · 、–O(halogenated R · ), –CN, –C(O)OH, –C(O)OR · , –NH2, –NHR · ,–NR · 2 or –NO2, where each R · Independently selected from C 1–4 Aliphatic, –CH2Ph, –O(CH2) 0–1 Ph or a 5- to 6-membered saturated, partially unsaturated or aryl ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen or sulfur, and wherein each R · is unsubstituted or, if preceded by halogen, substituted only by one or more halogens.
[0081] The optional substituents on the substitutable nitrogen are independently or Each of these are independently hydrogen, C 1–6aliphatic, unsubstituted -OPh, or unsubstituted 5- to 6-membered saturated, partially unsaturated or aryl ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or two independent occurrences of Together with its intervening atoms, it forms an unsubstituted 3- to 12-membered saturated, partially unsaturated, or aromatic monocyclic or bicyclic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein when C 1-6 When aliphatic, Optionally halogen, –R · 、-(halogenated R · ), -OH, –OR · 、–O(halogenated R · ), –CN, –C(O)OH, –C(O)OR · , –NH2, –NHR · ,–NR · 2 or –NO2, where each R · Independently selected from C 1–4 Aliphatic, –CH2Ph, –O(CH2) 0–1 Ph or a 5- to 6-membered saturated, partially unsaturated or aryl ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen or sulfur, and wherein each R · is unsubstituted or, if preceded by halogen, substituted only by one or more halogens.
[0082] "C1-C3 alkyl" refers to a straight or branched chain saturated hydrocarbon containing 1 to 3 carbon atoms. Examples of C1-C3 alkyl groups include, but are not limited to, methyl, ethyl, propyl, and isopropyl.
[0083] "C1-C5 alkyl" refers to a straight or branched saturated hydrocarbon containing 1 to 5 carbon atoms. Examples of C1-C5 alkyl include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl and neopentyl.
[0084] The alkyl group may be generally a lower alkyl group or a C1-C6 alkyl group. Examples of C1-C6 alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl and isohexyl.
[0085] Alkoxy groups can generally be lower alkyl groups or C1-C6 alkyl groups. Examples of C1-C6 alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl and isohexyl. Alkoxy groups are generally alkyl groups covalently bonded to oxygen.
[0086] The halogen can be F, Cl, Br or I.
[0087] Haloalkyl can be generally lower haloalkyl, or C1-C6 haloalkyl, or C1-C3 alkyl.The example of C1-C3 haloalkyl includes-CH2F,-CHF2,-CF3,-CH2Cl,-CHCl2,-CCl3,-CF2CF3,-CF2CF2H and-CH2CF3.
[0088] Haloalkoxy can generally be a haloalkyl group bonded to oxygen, such as a lower alkyl group, i.e. a C1-C6 haloalkyl group, or a C1-C3 haloalkyl group. Examples of C1-C3 haloalkyl groups include CH2F, CHF2, CF3, CH2Cl, CHCl2, CCl3, CF2CF3, CF2CF2H, and CH2CF3.
[0089] Cycloalkyl means a monocyclic saturated carbocyclic ring selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
[0090] Heterocycloalkyl means a monocyclic saturated carbocyclic ring selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, wherein a heteroatom such as nitrogen, oxygen or sulfur is bonded to two carbons in the ring.
[0091] Spirocycle means a monocyclic saturated carbocyclic ring selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, and optionally wherein a heteroatom such as nitrogen, oxygen or sulfur is bonded to two carbons in the ring.
[0092] As used herein, the term "pharmaceutically acceptable salt" refers to those salts that are suitable for contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic reaction, etc., and are commensurate with a reasonable benefit-risk ratio within the scope of reasonable medical judgment. Pharmaceutically acceptable salts are well known in the art. For example, SM Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, which is incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of the present invention include salts derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are amino groups with inorganic acids (such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid) or with organic acids (such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid) or by using other methods used in the art (such as ion exchange) to form salts. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like.
[0093] Salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N + (C 1–4 Representative alkali metal salts or alkaline earth metal salts include sodium salts, lithium salts, potassium salts, calcium salts, magnesium salts, etc. Where appropriate, other pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium and amine cations formed using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates and aryl sulfonates.
[0094] The present disclosure also includes pharmaceutical compositions comprising an effective amount of the disclosed compound and a pharmaceutically acceptable carrier. Representative "pharmaceutically acceptable salts" include, for example, water-soluble and water-insoluble salts such as acetate, amsonate (4,4-diaminostilbene-2,2-disulfonate), benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camphorsulfonate, carbonate, chloride, citrate, clavulanate, dihydrochloride, edetate, edisylate, propionate dodecyl sulfate, ethanesulfonate, fumarate, glucoheptonate, gluconate, glutamate, ethanol acyl p-aminophenylarsonic acid salt, hexafluorophosphate, hexylresorcinol salt, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoic acid The invention also includes but is not limited to the following: sodium bicarbonate, ...
[0095] A "subject" is a mammal, such as a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or a non-human primate, such as a monkey, chimpanzee, baboon, or rhesus monkey.
[0096] When used in conjunction with a compound, an "effective amount" refers to an amount effective to treat or prevent a disease in a subject as described herein.
[0097] As used in this disclosure, the term "carrier" encompasses carriers, excipients, and diluents and refers to a material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, which is involved in carrying or transporting an agent from one organ or part of the body to another organ or part of the body of a subject.
[0098] The term "treatment" with respect to a subject refers to improving at least one symptom of a disorder in the subject. Treatment includes curing, ameliorating or at least partially alleviating the disorder.
[0099] Unless otherwise indicated, the term "disorder" is used in this disclosure to mean, and is used interchangeably with, the terms disease, condition, or illness.
[0100] As used in this disclosure, the terms "administer," "administering," or "administration" refer to administering a disclosed compound or a pharmaceutically acceptable salt or composition of a disclosed compound directly to a subject, or administering a prodrug derivative or analog of a compound or a pharmaceutically acceptable salt or composition of a compound to a subject, which can form an equivalent amount of active compound in the subject's body.
[0101] The term "prodrug" as used in this disclosure means a compound that is convertible in vivo to a disclosed compound by metabolic means (eg, by hydrolysis, glucuronidation).
[0102] 2.1 Stereoisomers
[0103] The compounds of the present disclosure may contain, for example, double bonds, one or more asymmetric carbon atoms, and bonds with hindered rotation, and may therefore exist as stereoisomers, such as double bond isomers (i.e., geometric isomers (E / Z)), enantiomers, diastereomers, and atropisomers. Therefore, the scope of the present disclosure should be understood to encompass all possible stereoisomers of the compounds shown, including stereoisomerically pure forms (e.g., geometrically pure, enantiomerically pure, diastereomerically pure, and atropisomerically pure) and stereoisomeric mixtures (e.g., geometric isomers, enantiomers, diastereomers, and atropisomers, or mixtures of any of the foregoing) of any chemical structure (whole or part) disclosed herein, unless the stereochemistry is specifically identified.
[0104] If the stereochemistry of a structure or a portion of a structure is not represented by, for example, a bold line or a dotted line, the structure or a portion of a structure should be interpreted as covering all stereoisomers thereof. If the stereochemistry of a structure or a portion of a structure is represented by, for example, a bold line or a dotted line, the structure or a portion of a structure should be interpreted as covering only the indicated stereoisomers. For example, (1R)-1-methyl-2-(trifluoromethyl)cyclohexane is intended to cover (1R, 2R)-1-methyl-2-(trifluoromethyl)cyclohexane and (1R, 2S)-1-methyl-2-(trifluoromethyl)cyclohexane. The bond drawn with a wavy line represents that two stereoisomers are covered. Do not confuse it with the wavy line drawn perpendicular to the bond, which indicates the point of attachment of the group to the rest of the molecule.
[0105] As used herein, the term "stereoisomer" or "stereomerically pure" compound refers to one stereoisomer of a compound (e.g., geometric isomers, enantiomers, diastereomers, and atropisomers) that is substantially free of other stereoisomers of the compound. For example, a stereomerically pure compound having one chiral center will be substantially free of the mirror image enantiomer of the compound, and a stereomerically pure compound having two chiral centers will be substantially free of other enantiomers and diastereomers of the compound. A typical stereoisomerically pure compound comprises one stereoisomer of the compound greater than about 80% by weight and other stereoisomers of the compound equal to or less than about 20% by weight, one stereoisomer of the compound greater than about 90% by weight and other stereoisomers of the compound equal to or less than about 10% by weight, one stereoisomer of the compound greater than about 95% by weight and other stereoisomers of the compound equal to or less than about 5% by weight, or one stereoisomer of the compound greater than about 97% by weight and other stereoisomers of the compound equal to or less than about 3% by weight. The present disclosure also encompasses pharmaceutical compositions comprising a stereoisomerically pure form of any compound disclosed herein and the uses of a stereoisomerically pure form. In addition, the present disclosure also encompasses pharmaceutical compositions comprising a mixture of stereoisomers of any compound disclosed herein and the uses of the pharmaceutical compositions or mixtures of stereoisomers. These stereoisomers or mixtures thereof can be synthesized according to methods well known in the art and methods disclosed herein. Mixtures of stereoisomers can be split using standard techniques, such as chiral columns or chiral resolving agents. See, e.g., Jacques et al., Enantiomers, Racemates and Resolutions (Wiley-Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725; Eliel, Stereochemistry of Carbon
[0106] Compounds (McGraw-Hill, NY, 1962); and Wilen, Tables of Resolving Agents and Optical Resolutions, p. 268 (Eliel, ed., Univ. of Notre Dame Press, Notre Dame, IN, 1972).
[0107] 2.2 Tautomers
[0108] As known to those skilled in the art, certain compounds disclosed herein may exist in one or more tautomeric forms. Since only one specific chemical structure can be used to represent only one tautomeric form, it should be understood that, for convenience, reference to a compound of a given structural formula includes all other possible tautomers of the structural formula. For example, the following is an illustration of tautomers of a compound of formula I', wherein R5 = H:
[0109]
[0110] Those skilled in the art will recognize that under standard conditions, the left tautomer is clearly the major tautomer of these two structures, and this example is given for illustrative purposes only. Therefore, the scope of the present disclosure should be understood to encompass all tautomeric forms of the compounds disclosed herein.
[0111] 2.3 Isotope-labeled compounds
[0112] In addition, the scope of the present disclosure includes all pharmaceutically acceptable isotope-labeled compounds of the compounds disclosed herein (such as compounds of Formula I) in which one or more atoms are replaced by atoms having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes suitable for inclusion in the compounds disclosed herein include isotopes of hydrogen (such as 2 H and 3 H), isotopes of carbon (such as n C. 13 C and 14 C), isotopes of chlorine (such as 36 Cl), isotopes of fluorine (such as 18 F), isotopes of iodine (such as 123 I and 125 I), isotopes of nitrogen (such as 13 N and 15 N), oxygen isotopes (such as 15 0. 17 0 and 18 0), isotopes of phosphorus (such as 32 P) and isotopes of sulfur (such as 35 S). Certain isotopically labeled compounds of Formula I (e.g., compounds incorporating a radioactive isotope) are useful in drug and / or substrate tissue distribution studies. The radioactive isotope tritium ( 3 H) and carbon-14 ( 14 C) may be particularly useful for this purpose in view of its ease of incorporation and ease of detection. 2H or D) substitution may offer certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements and therefore may be advantageous in some circumstances. Use of positron emitting isotopes such as n C. 18 F. 15 0 and 13 N) substitution can be used for positron emission tomography (PET) studies, such as examining target occupancy. Isotope-labeled compounds of the compounds disclosed herein can generally be prepared by those skilled in the art by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying general synthetic schemes and examples using appropriate isotope-labeled reagents instead of the unlabeled reagents previously used.
[0113] 2.4 Solvates
[0114] As noted above, the compounds disclosed herein and stereoisomers, tautomers, and isotopically labeled forms thereof, or pharmaceutically acceptable salts of any of the foregoing compounds, may exist in solvated or unsolvated forms.
[0115] As used herein, the term "solvate" refers to a molecular complex comprising a compound described herein or a pharmaceutically acceptable salt thereof and a stoichiometric or non-stoichiometric amount of one or more pharmaceutically acceptable solvent molecules. If the solvent is water, the solvate is referred to as a "hydrate."
[0116] Therefore, the scope of the present disclosure should be understood to encompass all solvents of the compounds disclosed herein and stereoisomers, tautomers, and isotopically labeled forms thereof, or pharmaceutically acceptable salts of any of the foregoing compounds.
[0117] 3. Description of exemplary embodiments:
[0118] In some embodiments, the present invention provides a compound of formula (I)
[0119]
[0120] Where Z is
[0121]
[0122] And among them
[0123] R1 is hydrogen or optionally substituted cycloalkyl, aryl or C1-C3 alkylaryl, each of which is optionally substituted with one or more substituents independently selected from halogen, alkyl, haloalkyl, alkoxy, C1-C3 haloalkoxy or heterocycle;
[0124] R2 is H, halogen, deuterium, alkyl, haloalkyl, C1-C3 alkoxy and C1-C3 haloalkoxy, hydroxyalkyl, alkoxyalkyl, cycloalkyl including cyclopropyl, C1-C3 alkylaryl, or Substituted or unsubstituted aryl and aralkyl, or including Amides of, wherein R9 is independently selected from C1-C3 alkyl, cycloalkyl (including cyclopropyl) and substituted or unsubstituted phenyl;
[0125] or R1 and R2 together with the thiazole ring form an optionally substituted 5-, 6- or 7-membered fused 1,2-carbocyclic ring system, wherein the ring carbons of the 5-, 6- or 7-membered fused ring are optionally substituted with one or more atoms selected from N, O and S. The fused 5-, 6- or 7-membered ring is optionally substituted independently with one or more halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, or an optionally substituted aromatic ring;
[0126] Or R1 and R2 together with the carbon to which they are attached form a substituted or unsubstituted or substituted
[0127]
[0128] R3 is hydrogen, C1-C3 alkyl or C1-C3 haloalkyl;
[0129] Each R4 is independently hydrogen, C1-C3, halogen, substituted or unsubstituted phenyl, cycloalkyl including cyclopropyl, C1-C3 alkyl, C1-C3 alkylaryl, C1-C3 haloalkyl, C1-C3 alkoxy or C1-C3 haloalkoxy;
[0130] R5 is hydrogen, C1-C3 alkyl or C1-C3 haloalkyl;
[0131] R6 is hydrogen, CD3, alkyl, cycloalkyl, haloalkyl or
[0132]
[0133] Each R7 is independently hydrogen, haloalkyl, haloalkyl or cycloalkyl;
[0134] R8 is hydrogen, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;
[0135] n is 0, 1 or 2;
[0136] p is 0, 1, 2 or 3;
[0137] or a pharmaceutically acceptable salt, prodrug, solvate, hydrate or stereoisomer thereof.
[0138] As generally defined above, R1 is optionally substituted aryl or C1-C3 alkylaryl, substituted with one or more substituents independently selected from halogen, alkyl, haloalkyl, alkoxy, 3-F, 4-oxetanylphenyl and C1-C3 haloalkoxy.
[0139] In some embodiments, R1 is optionally substituted aryl.
[0140] In some embodiments, R1 is
[0141] Wherein R is independently halogen, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Cycloalkyl or C 1-3 halocycloalkyl; and wherein m is 0-4.
[0142] In some embodiments, R1 is
[0143] Wherein R is independently halogen, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Cycloalkyl or C 1-3 halocycloalkyl; and wherein m is 1-4.
[0144] In some embodiments, R1 is
[0145] Wherein R is independently halogen, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Cycloalkyl or C 1-3 halocycloalkyl; and wherein m is 1-3.
[0146] In some embodiments, R1 is
[0147] Wherein R is independently halogen, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Cycloalkyl or C 1-3 halocycloalkyl; and wherein m is 1-2.
[0148] In some embodiments, R1 is
[0149] Wherein R is independently halogen, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Cycloalkyl or C 1-3 halocycloalkyl; and wherein m is 1.
[0150] In some embodiments, R1 is
[0151]
[0152] In some embodiments, R1 is
[0153]
[0154] In some embodiments, R1 is
[0155]
[0156] In some embodiments, R1 is
[0157]
[0158] In some embodiments, R1 is
[0159]
[0160] In some embodiments, R1 is
[0161]
[0162] In some embodiments, R1 is
[0163]
[0164] In some embodiments, R1 is
[0165]
[0166] In some embodiments, R1 is
[0167]
[0168] In some embodiments, R1 is
[0169]
[0170] In some embodiments, R1 is
[0171]
[0172] In some embodiments, R1 is phenyl substituted by a heterocycle, including but not limited to:
[0173]
[0174] The aryl group may be optionally substituted by 3-halogen.
[0175] In some embodiments, R1 is selected from the groups listed in Table 1 below in the R1 position.
[0176] As generally defined above, R2 is hydrogen, halogen, alkyl, cycloalkyl, C1-C3 alkylaryl, haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, hydroxyalkyl or alkoxyalkyl.
[0177] In some embodiments, R2 is hydrogen or deuterium.
[0178] In some embodiments, R2 is halogen.
[0179] In some embodiments, R2 is F, Cl, Br or I.
[0180] In some embodiments, R2 is F, Cl, or Br.
[0181] In some embodiments, R2 is F or Cl.
[0182] In some embodiments, R2 is F.
[0183] In some embodiments, R2 is Cl.
[0184] In some embodiments, R2 is Br.
[0185] In some embodiments, R2 is 1.
[0186] In some embodiments, R2 is alkyl.
[0187] In some embodiments, R2 is methyl, ethyl, n-propyl, or isopropyl.
[0188] In some embodiments, R2 is methyl.
[0189] In some embodiments, R2 is C1-C3 alkylaryl.
[0190] In some embodiments, R2 is methylaryl.
[0191] In some embodiments, R2 is cycloalkyl, including cyclopropyl, including
[0192] In some embodiments, R2 is aryl or aralkyl, including
[0193] In some embodiments, R2 is cyclopropyl.
[0194] In some embodiments, R2 is cyclobutyl.
[0195] In some embodiments, R2 is cyclopentyl.
[0196] In some embodiments, R2 is cyclopentenyl.
[0197] In some embodiments, R2 is cyclohexyl.
[0198] In some embodiments, R2 is cyclohexenyl.
[0199] In some embodiments, R2 is halomethyl.
[0200] In some embodiments, R2 is fluoromethyl, fluoroethyl, or fluoropropyl.
[0201] In some embodiments, R2 is fluoromethyl.
[0202] In some embodiments, R2 is trifluoromethyl.
[0203] In some embodiments, R2 is C1-C3 alkoxy.
[0204] In some embodiments, R2 is an amide selected from The group consisting of, wherein R9 is independently selected from C1-C3 alkyl, cycloalkyl (including cyclopropyl) and substituted or unsubstituted phenyl.
[0205] In some embodiments, R2 is OMe or OEt or O i Pr.
[0206] In some embodiments, R2 is OMe.
[0207] In some embodiments, R2 is OCF3.
[0208] In some embodiments, R2 is OCH2F.
[0209] In some embodiments, R2 is CH2OH or CH2CH2OH or CH2CH2CH2OH or CH2C(OH)(CH3)2.
[0210] In some embodiments, R2 is CH2OCH3 or CH2CH2OCH3 or CH2OCH2CH3.
[0211] In some embodiments, R2 is selected from the groups listed in Table 1 below in the R2 position.
[0212] As generally defined above, R1 and R2 together with the thiazole ring form a 5-, 6- or 7-membered fused 1,2-carbocyclic ring system, wherein the ring carbons of the 5-, 6- or 7-membered ring (excluding the 1,2-thiazole fused ring carbons) are optionally substituted with one or more ring atoms selected from N, O and S. In addition, R1 and R2 may together form a benzene ring or a fused naphthalene ring fused to the thiazole ring. The fused 5-, 6- or 7-membered ring is optionally independently substituted with one or more halogens, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy or C1-C3 haloalkoxy.
[0213] In some embodiments, R1 and R2 are taken together to form a 6-membered ring fused to the thiazole.
[0214] In some embodiments, R1 and R2 are taken together to form a 5-membered ring fused to the thiazole.
[0215] In some embodiments, R1 and R2 are taken together to form a 7-membered ring fused to the thiazole.
[0216] In some embodiments, R1 and R2 together are optionally substituted
[0217]
[0218] In some embodiments, R1 and R2 together are optionally substituted
[0219]
[0220] In some embodiments, R1 and R2 together are selected from the R1 / R2 linking groups in the R1 and R2 positions shown in Table 1 below.
[0221] As generally described above, R3 is H, C1-C3 alkyl or C1-C3 haloalkyl.
[0222] In some embodiments, R3 is hydrogen.
[0223] In some embodiments, R3 is halogen.
[0224] In some embodiments, R3 is F, Cl, Br or I.
[0225] In some embodiments, R3 is F, Cl or Br.
[0226] In some embodiments, R3 is F or Br.
[0227] In some embodiments, R3 is F or Cl.
[0228] In some embodiments, R3 is Cl or Br.
[0229] In some embodiments, R3 is Cl.
[0230] In some embodiments, R3 is F.
[0231] In some embodiments, R3 is C1-C3 alkyl or C1-C3 haloalkyl.
[0232] In some embodiments, R3 is C1-C3 alkyl.
[0233] In some embodiments, R3 is C1-C3 haloalkyl.
[0234] In some embodiments, R3 is methyl or ethyl.
[0235] In some embodiments, R3 is selected from the groups listed in Table 1 below in the R3 position.
[0236] As generally defined above, each R4 is independently hydrogen, deuterium, CD3, phenyl, cyclopropyl, halogen, C1-C3 alkyl, C1-C3 haloalkyl, -C1-C3 alkoxy, C1-C3 alkylaryl, C1-C3 haloalkoxy.
[0237] In some embodiments, R4 is independently H.
[0238] In some embodiments, R4 is independently halogen.
[0239] In some embodiments, R4 is independently F, Cl, Br or I.
[0240] In some embodiments, R4 is independently F, Cl or Br.
[0241] In some embodiments, R4 is independently F or Br.
[0242] In some embodiments, R4 is independently F or Cl.
[0243] In some embodiments, R4 is independently Cl or Br.
[0244] In some embodiments, R4 is independently Cl.
[0245] In some embodiments, R4 is independently F.
[0246] In some embodiments, R4 is independently Br.
[0247] In some embodiments, R4 is independently 1.
[0248] In some embodiments, R4 is independently C1-C3 alkyl.
[0249] In some embodiments, R4 is independently methyl, ethyl, n-propyl, or independently is isopropyl.
[0250] In some embodiments, R4 is independently methyl.
[0251] In some embodiments, R4 is independently C1-C3 alkylaryl.
[0252] In some embodiments, R4 is independently CH2-aryl.
[0253] In some embodiments, R4 is independently haloalkyl.
[0254] In some embodiments, R4 is independently fluoromethyl, fluoroethyl, or fluoropropyl.
[0255] In some embodiments, R4 is independently fluoromethyl.
[0256] In some embodiments, R4 is independently trifluoromethyl.
[0257] In some embodiments, R4 is independently C1-C3 alkoxy.
[0258] In some embodiments, R4 is independently OMe or OEt or O i Pr.
[0259] In some embodiments, R4 is independently OMe.
[0260] In some embodiments, R4 is independently OCF3.
[0261] In some embodiments, R4 is independently OCH2F.
[0262] In some embodiments, R4 is independently CH2OH or CH2CH2OH or CH2CH2CH2OH or CH2C(OH)(CH3)2.
[0263] In some embodiments, R4 is independently CH2OCH3 or CH2CH2OCH3 or CH2OCH2CH3.
[0264] In some embodiments, R4 is independently selected from the groups at the R4 position listed in Table 1 below.
[0265] As generally defined above, R5 is hydrogen, C1-C3 alkyl or C1-C3 haloalkyl.
[0266] In some embodiments, R5 is H.
[0267] In some embodiments, R5 is C1-C3 alkyl or C1-C3 haloalkyl.
[0268] In some embodiments, R5 is C1-C3 alkyl.
[0269] In some embodiments, R5 is methyl, ethyl, or propyl.
[0270] In some embodiments, R5 is methyl or ethyl.
[0271] In some embodiments, R5 is methyl.
[0272] In some embodiments, R5 is ethyl or propyl.
[0273] In some embodiments, R5 is ethyl.
[0274] In some embodiments, R5 is propyl.
[0275] In some embodiments, R5 is n-propyl.
[0276] In some embodiments, R5 is isopropyl.
[0277] In some embodiments, R5 is C1-C3 haloalkyl.
[0278] In some embodiments, R5 is fluoromethyl, fluoroethyl, or fluoropropyl.
[0279] In some embodiments, R5 is fluoromethyl.
[0280] In some embodiments, R5 is trifluoromethyl.
[0281] In some embodiments, R5 is selected from the groups listed in Table 1 below in the R5 position.
[0282] As generally described above, R6 is hydrogen, CD3, alkyl, cycloalkyl, haloalkyl or
[0283]
[0284] In some embodiments, R6 is hydrogen.
[0285] In some embodiments, R6 is -CD3.
[0286] In some embodiments, R6 is C1-C6 alkyl or C1-C6 haloalkyl.
[0287] In some embodiments, R6 is C1-C3 alkyl or C1-C3 haloalkyl.
[0288] In some embodiments, R6 is C1-C3 alkyl.
[0289] In some embodiments, R5 is methyl, ethyl, or propyl.
[0290] In some embodiments, R6 is methyl or ethyl.
[0291] In some embodiments, R6 is methyl.
[0292] In some embodiments, R6 is ethyl or propyl.
[0293] In some embodiments, R6 is ethyl.
[0294] In some embodiments, R6 is propyl.
[0295] In some embodiments, R6 is n-propyl.
[0296] In some embodiments, R6 is isopropyl.
[0297] In some embodiments, R6 is C1-C3 haloalkyl.
[0298] In some embodiments, R6 is fluoromethyl, fluoroethyl, or fluoropropyl.
[0299] In some embodiments, R6 is fluoromethyl.
[0300] In some embodiments, R6 is trifluoromethyl.
[0301] In some embodiments, R6 is C1-C6 cycloalkyl
[0302] In some embodiments, R6 is selected from the groups listed in Table 1 below in the R6 position.
[0303] As generally described above, each R7 is independently hydrogen, alkyl, haloalkyl, cycloalkyl or halogen. In some embodiments, each R7 is independently hydrogen.
[0304] In some embodiments, R7 is H.
[0305] In some embodiments, R7 is C1-C6 alkyl or C1-C6 haloalkyl.
[0306] In some embodiments, R7 is C1-C3 alkyl or C1-C3 haloalkyl.
[0307] In some embodiments, R7 is C1-C3 alkyl.
[0308] In some embodiments, R5 is methyl, ethyl, or propyl.
[0309] In some embodiments, R7 is methyl or ethyl.
[0310] In some embodiments, R7 is methyl.
[0311] In some embodiments, R7 is ethyl or propyl.
[0312] In some embodiments, R7 is ethyl.
[0313] In some embodiments, R7 is propyl.
[0314] In some embodiments, R7 is n-propyl.
[0315] In some embodiments, R7 is isopropyl.
[0316] In some embodiments, R7 is C1-C3 haloalkyl.
[0317] In some embodiments, R7 is fluoromethyl, fluoroethyl, or fluoropropyl.
[0318] In some embodiments, R7 is fluoromethyl.
[0319] In some embodiments, R7 is trifluoromethyl.
[0320] In some embodiments, R7 is C1-C6 cycloalkyl
[0321] In some embodiments, R7 is selected from the groups listed in Table 1 below in the R7 position.
[0322] As generally described above, R8 is hydrogen, alkyl, haloalkyl, cycloalkyl, halocycloalkyl. In some embodiments, R8 is hydrogen.
[0323] In some embodiments, R8 is C1-C6 alkyl or C1-C6 haloalkyl.
[0324] In some embodiments, R8 is C1-C3 alkyl or C1-C3 haloalkyl.
[0325] In some embodiments, R8 is C1-C3 alkyl.
[0326] In some embodiments, R5 is ethyl or propyl.
[0327] In some embodiments, R8 is methyl or ethyl.
[0328] In some embodiments, R8 is methyl.
[0329] In some embodiments, R8 is ethyl or propyl.
[0330] In some embodiments, R8 is ethyl.
[0331] In some embodiments, R8 is propyl.
[0332] In some embodiments, R8 is n-propyl.
[0333] In some embodiments, R8 is isopropyl.
[0334] In some embodiments, R8 is C1-C3 haloalkyl.
[0335] In some embodiments, R8 is fluoromethyl, fluoroethyl, or fluoropropyl.
[0336] In some embodiments, R8 is fluoromethyl.
[0337] In some embodiments, R8 is trifluoromethyl.
[0338] In some embodiments, R8 is C1-C8 cycloalkyl
[0339] In some embodiments, R8 is selected from the groups listed in Table 1 below in the R8 position.
[0340] As generally described above, n is 0, 1 or 2.
[0341] In some embodiments, n is 0 or 1.
[0342] In some embodiments, n is 0 or 2.
[0343] In some embodiments, n is 1 or 2.
[0344] In some embodiments, n is 0.
[0345] In some embodiments, n is 1.
[0346] In some embodiments, n is 2.
[0347] As generally described above, p is 0, 1, 2 or 3.
[0348] In some embodiments, p is 0, 1 or 2.
[0349] In some embodiments, p is 0, 1 or 3.
[0350] In some embodiments, p is 1, 2, or 3.
[0351] In some embodiments, p is 0 or 1.
[0352] In some embodiments, p is 0 or 2.
[0353] In some embodiments, p is 0 or 3.
[0354] In some embodiments, p is 1 or 2.
[0355] In some embodiments, p is 1 or 3.
[0356] In some embodiments, p is 2 or 3.
[0357] In some embodiments, p is 0.
[0358] In some embodiments, p is 1.
[0359] In some embodiments, p is 2.
[0360] In some embodiments, p is 3.
[0361] 4. General Methods for Providing Compounds of the Invention
[0362] The compounds described herein can generally be prepared or isolated by synthetic and / or semi-synthetic methods known to those skilled in the art for similar compounds and by the methods described in detail in the Examples herein.
[0363] Those skilled in the art will recognize that various functional groups such as aliphatic groups, alcohols, carboxylic acids, esters, amides, aldehydes, halogens and nitriles present in the compounds of the present invention can be interconverted by techniques well known in the art, including but not limited to reduction, oxidation, esterification, hydrolysis, partial oxidation, partial reduction, halogenation, dehydration, partial hydration and hydration. See, for example, "March's Advanced Organic Chemistry", 5th edition, editors: Smith, MB and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are incorporated herein by reference. Such interconversions may require one or more of the above techniques, and certain methods for synthesizing the disclosed compounds are described herein.
[0364] Scheme 1 illustrates a general method for preparing compounds of formula (I). In one aspect, certain compounds of the present invention of formula (I) or its subformulae are generally prepared according to Scheme 1 as shown below:
[0365]
[0366]
[0367] Scheme 1 In one embodiment, the compound of formula (II) is
[0368]
[0369] wherein R3, R4 and n are as defined above, react with a compound of formula (III):
[0370]
[0371] wherein R1, R2 and R5 are as defined above, to provide a compound of formula (IV):
[0372]
[0373] wherein R1 to R5 and n are as defined above. The compound of formula (IV) is hydrolyzed according to methods known to those skilled in the art, such as alkaline hydrolysis, to provide a compound of formula (V):
[0374]
[0375] wherein R1 to R5 and n are as defined above; or a salt thereof.
[0376] Then the compound of formula (V) or its salt is reacted with the compound of formula (VI),
[0377]
[0378] in
[0379] R6, R7, R8 and p are as defined above;
[0380] Optionally reacting in the presence of a strong acid to provide a salt of formula (VIIa) or a compound of formula (VII) or a salt thereof:
[0381]
[0382] wherein R1 to R8, n and p are as defined above, and wherein A is a counter ion known to those of ordinary skill in the art.
[0383] Salts of formula (VIIa) and / or compounds of formula (VII) or salts thereof may be reacted with a reducing agent, for example a borohydride, such as triacetoxyborohydride, to provide compounds of formula (I).
[0384] Solution 2.
[0385] Generally as shown in Scheme 1, a starting material compound comprising structure (II) is coupled with a compound of general structure (III) to provide a compound of general structure (IV). The compound of general structure (IV) can then be deprotected via a hydrolysis reaction to obtain a compound of general structure (V). (V) is reacted with an aldehyde (VI) to obtain (VIIa), which can be reduced by various well-known methods to obtain compound (I). Those skilled in the art will recognize that compound (V) can be converted to compound (I) via well-known reductive amination or other similar methods.
[0386] In the case of compounds of structure (V) where R3 is hydrogen, a Schiff base of formula (VII) can be formed and reduced simultaneously or subsequently to give compounds (I") wherein R3 is hydrogen.
[0387] 4.1. Synthesis of specific intermediates
[0388] abbreviation
[0389] The following abbreviations are used herein.
[0390] equiv or eq: molar equivalent
[0391] o / n: Overnight
[0392] rt: room temperature
[0393] UV: Ultraviolet
[0394] h: hours
[0395] HPLC: High Pressure Liquid Chromatography
[0396] Rt: residence time
[0397] LC / MS: Liquid chromatography mass spectrometry
[0398] NMR: Nuclear Magnetic Resonance
[0399] CC: Column chromatography
[0400] TLC: Thin layer chromatography
[0401] sat: saturated
[0402] aq: water-based
[0403] Ac:Acetyl
[0404] DCM: dichloromethane
[0405] DCE: dichloroethane
[0406] DEA: Diethylamine
[0407] DMF: dimethylformamide
[0408] DMSO: dimethyl sulfoxide
[0409] ACN or MeCN: acetonitrile
[0410] DIPEA: diisopropylethylamine
[0411] EA or EtOAc: Ethyl acetate
[0412] TEA: triethylamine
[0413] THF: Tetrahydrofuran
[0414] NCS: N-chlorosuccinimide
[0415] PE: Petroleum ether
[0416] Prep.: Preparation
[0417] TFA: trifluoroacetic acid
[0418] FA: Formic acid
[0419] h: hours
[0420] min: minutes
[0421] s or sec: seconds
[0422] STAB: Sodium triacetoxyborohydride
[0423] Cy:Cyclohexyl
[0424] Tol: Toluene
[0425] General information
[0426] All air or moisture sensitive reactions were performed under positive pressure of nitrogen using oven-dried glassware. Chemical reagents and anhydrous solvents were obtained from commercial sources and used as received. Preparative purification was performed on a Waters semi-preparative HPLC. The column used was a Phenomenex Luna C18 (10 μm, 250×75 mm) with a flow rate of 45 mL / min. The mobile phase consisted of acetonitrile and water (each containing 0.1% hydrochloric acid). A gradient of 50% to 80% acetonitrile was used over 23 min during purification. Fraction collection was triggered by UV detection (220 nm). Purity analysis was determined by a method called final QC. Method: Analysis was performed on an Agilent 1260 Infinity Series LCMS: LCMS Long Gradient Equivalent 5% to 100% acetonitrile (0.018% trifluoroacetic acid) in water (0.037% trifluoroacetic acid) over 3 min, with a run time of 4 min and a flow rate of 1 mL / min. A Shim-pack Velox SP-C18 2.7 μm column (3.0×30 mm) was used at 50° C. Purity was determined using an Agilent diode array detector. Mass determination was performed using an Agilent 1260 mass spectrometer with electrospray ionization in positive mode. 1H and 19F NMR spectra were recorded on a Bruker 400 (400) MHz or 600 (376) MHz spectrometer.
[0427] Intermediate compounds of formula II, II-1 and II-2
[0428]
[0429] Intermediate II can be reacted with intermediate III to produce a compound of formula (IV).
[0430] In another embodiment, the compound of formula II-1 and / or II-2 can be reacted with a specific intermediate compound of formula III below to produce a compound of formula (IV):
[0431]
[0432] Solution 3
[0433] Preparation examples of intermediates
[0434] Preparation Example 1: Synthesis of 5-acetylaminopyridine-2-sulfonyl chloride (II-1, Scheme 4).
[0435]
[0436] Solution 4
[0437] Synthesis of 4-nitro-2-mercaptopyridine (C). At 25 ° C, under N2, thiourea (3.99 g, 52.48 mmol, 1.04 eq) was added to a mixture of 2-chloro-4-nitropyridine ((A) 8 g, 50.46 mmol, 1 eq) in EtOH (120 mL) at one time. The mixture was stirred at 25 ° C for 10 min, then heated to 85 ° C and stirred for 48 hours. LC-MS showed that the starting material was completely consumed. The mixture was cooled to 25 ° C and filtered to obtain crude compound B. The residue was poured into water (20 mL) treated with 20% NaOH (100 mL). The mixture was stirred for 30 min and filtered. The pH of the solution was adjusted to 7 with HCl (2 M), and the precipitated solid was collected by filtration to obtain compound C (3.5 g, 42% yield, 95% purity), which was a red solid. 1 HNMR (400MHz, CDCl3) δ8.48 (d, J = 2.5 Hz, 1H), 7.92 (dd, J = 9.6, 2.6 Hz, 1H), 7.39 (d, J = 9.6 Hz, 1H).
[0438] N-(6-Mercapto-3-pyridyl)acetamide (D). At 0 ° C, under N2, Na2(S2O4) (5.85 g, 33.62 mmol, 7.32 mL, 3.5 eq) was added to a mixture of compound C (1.58 g, 9.61 mmol, 1 eq) in H2O (15 mL) at one time. Acetic anhydride (1.37 g, 13.45 mmol, 1.26 mL, 1.4 eq) was then added. The mixture was stirred at 0 ° C for 2 hours. LC-MS showed that the starting material was completely consumed. The yellow precipitate was filtered, washed with water, and dried to obtain a yellow solid. A yellow solid (940 mg, 58% yield) was obtained. 1 H NMR (400MHz, DMSO) δ13.35 (s, 1H), 10.07 (s, 1H), 8.22 (d, J = 3.8Hz, 1H), 7.37–7.22 (m, 2H), 2.03 (s, 3H).
[0439] 5-Acetylaminopyridine-2-sulfonyl chloride (II-1). At 0 ℃, under N2, N-chlorosuccinimide (2.2g, 16.65mmol, 4eq) was added once in a mixture of compound D (700mg, 4.16mmol, 1eq) in acetic acid (18mL) and H2O (2mL). The mixture was stirred at 25 ℃ for 4 hours. Thin layer chromatography showed that the starting material was completely consumed. The mixture was diluted with water (10ml) and extracted with ethyl acetate (3x 10mL). The combined organic phases were washed with brine (15mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo to obtain 5-acetylaminopyridine-2-sulfonyl chloride (II-1) (800mg, 78% yield, 95% purity), which was an orange solid. 1 H NMR (400MHz, DMSO) δ 11.30 (s, 1H), 9.07 (s, 1H), 8.52 (d, J = 8.8Hz, 1H), 8.15 (d, J = 8.7Hz, 1H), 2.18 (d, J = 11.4Hz, 3H).
[0440] Preparation Example 2: Synthesis of 5-acetylamino-3-methylpyridine-2-sulfonyl chloride (II-2, Scheme 5).
[0441]
[0442] Solution 5
[0443] The mixture of thiourea (2.21g, 28.97mmol) and 2-chloro-3-methyl-5-nitropyridine (5g, 28.97mmol) in EtOH (50mL) is degassed and purged 3 times with dry N2. The mixture is stirred at 85 DEG C for 4h under N2 atmosphere to obtain a yellow precipitate. The precipitate is filtered, washed with water (200mL), and dried to obtain a yellow solid. Excess water is removed from the residue in a vacuum to obtain 3-methyl-5-nitropyridine-2-ylthiocarbamide ester (4.64g, 21.9mmol, 75.5% yield), which is a yellow solid.
[0444] To a solution of 3-methyl-5-nitropyridine-2-ylthiocarbamide ester (4.64 g, 21.86 mmol) in H2O (9 mL) was added NaOH (54 mL, 20% H2O solution). The mixture was stirred at 25 ° C for 1 hour. The insoluble material in the reaction mixture was filtered and the pH was adjusted to 7 with HCl (aqueous solution, 3M in H2O solution), and filtered to obtain a crude product. Excess water was removed from the filter residue under reduced pressure to obtain 3-methyl-5-nitropyridine-2-thiol (3 g, 17.6 mmol, 81% yield) as a red solid. LCMS: (M+H) + =171.2.
[0445] Under N2, to a mixture of 3-methyl-5-nitropyridine-2-thiol (3g, 17.63mmol) in H2O (60mL), Na2S2O4 (10.74g, 61.7mmol, 13.4mL) was added, followed by addition of ethyl acetate (2.52g, 24.7mmol, 2.31mL), and the mixture was stirred at 0°C for 0.5 hours under N2 atmosphere. The yellow precipitate was filtered, washed with water (100mL), and dried to obtain a yellow solid. Excess water was removed from the filter residue under reduced pressure to obtain N-(6-mercapto-5-methylpyridin-3-yl)acetamide (1.3g, 7.13mmol, 40.5% yield) as a yellow solid.
[0446] A solution of N-(6-mercapto-5-methylpyridin-3-yl)acetamide (1.3g, 7.13mmol) in AcOH (10mL) and H2O (2mL) was degassed and purged 3 times with N2, and then NCS (3.33g, 24.97mmol) was added. The mixture was stirred at 0°C for 0.5h under N2 atmosphere. The reaction mixture was diluted with ethyl acetate (10mL x 3), washed with brine (15mL x 2), dried over Na2SO4 and concentrated to dryness. The residue was purified by column chromatography (silica gel, 100-200 mesh, 70% ethyl acetate in petroleum ether). 5-acetamido-3-methylpyridine-2-sulfonyl chloride (II-2, 1.1g, 2.48mmol, 35% yield) was obtained as a brown solid. LCMS: (M+H) + =249.1.
[0447] Preparation Example 3: Synthesis of 4-(4-chloro-3-fluorophenyl)thiazol-2-amine (III-1, Scheme 6).
[0448]
[0449] Solution 6
[0450] At 25 ℃, under N2, to 1-(4-chloro-3-fluorophenyl) ethyl-1-ketone (2.27g, 13.15mmol, 1eq), triethylamine (2.00g, 19.73mmol, 2.75mL, 1.5eq) and thiourea (2.50g, 32.88mmol, 2.5eq) in MeCN (20mL) mixture, carbon tetrabromide (6.54g, 19.73mmol, 1.5eq) was added once. The mixture was stirred at 25 ℃ for 16 hours. LC-MS showed that acetophenone was completely consumed, and a new main peak with the required mass was detected. The mixture was concentrated under reduced pressure and the resulting residue was poured into water (50mL) and stirred for 10min. The aqueous phase was extracted with ethyl acetate (3x20mL). The combined organic phase was washed with brine (50mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / ethyl acetate=1 / 0, 1 / 1) to give 4-(4-chloro-3-fluorophenyl)thiazol-2-amine (III-1) as a yellow solid (2.88 g, 96% yield).
[0451] Preparation Example 4: Synthesis of 4-(3-chloro-4-fluorophenyl)-1,3-thiazol-2-ylamine (III-2, Scheme 7).
[0452]
[0453] Solution 7
[0454] To a mixture of 1-(3-chloro-4-fluorophenyl) second-1-ketone (15g, 86.91mmol, 1eq) and thiourea (9.92g, 130.37mmol, 1.5eq) in MeCN (100mL), CBr (43.23g, 130.37mmol, 1.5eq) and EtN (13.19g, 130.37mmol, 18.15mL, 1.5eq) is degassed and purged three times with N. The mixture is stirred at 25 °C for 16 hours under N atmosphere. LC-MS shows that starting material is completely consumed. The reaction mixture is diluted with 1N HCl (50mL), extracted with ethyl acetate (200mL) and water (200mL), then NHCl is added, and a solid is precipitated and filtered. The filter cake was dried under reduced pressure to give 4-(3-chloro-4-fluorophenyl)-1,3-thiazol-2-ylamine (III-2) (3.5 g, 14% yield, 80% purity) as a red solid. 1 H NMR (400MHz, DMSO-d6) 7.96 (dd, J = 2.1, 7.3 Hz, 1H), 7.79 (ddd, J = 2.2, 4.8, 8.7 Hz, 1H), 7.40 (t, J = 9.0 Hz, 1H), 7.14 (s, 3H).
[0455] Preparation Example 5: Synthesis of 4-(3,4-difluorophenyl)-1,3-thiazol-2-amine (III-3, Scheme 8).
[0456]
[0457] Solution 8
[0458] To a mixture of 1-(3,4-difluorophenyl)ethan-1-one (20 g, 128.10 mmol, 16.00 mL) and thiourea (14.63 g, 192.15 mmol) in acetonitrile (300 mL) was added triethylamine (19.44 g, 192.15 mmol, 26.74 mL) and carbon tetrabromide (63.72 g, 192.15 mmol). The mixture was stirred at 25 ° C for 16 hours. LC-MS showed that the reaction was complete. The reaction mixture was concentrated under reduced pressure to remove the solvent. The resulting residue was ground with water (200 mL) and extracted with EtOAc (150 mL x 3). The combined organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure to obtain a residue, which was purified by flash silica gel chromatography ( 220g Silica gel flash column, 22% to 30% ethyl acetate / petroleum ether gradient elution @120mL / min), petroleum ether / ethyl acetate = 3:1, Rf = 0.3) to obtain 4-(3,4-difluorophenyl)-1,3-thiazol-2-amine (III-3, 12.7 g, 58.65 mmol, 6% yield, 98% purity) as a brown solid. LC-MS: (M+H) + =212.7; 1 H NMR (400MHz, DMSO-d6): 7.78 (ddd, J = 1.9, 8.0, 12.4Hz, 1H), 7.66-7.61 (m, 1H), 7.46-7.36 (m, 1H), 7.11 (br d, J = 5.5Hz, 3H).
[0459] Preparation Example 6: Synthesis of 4-(3-chloro-4-fluorophenyl)-5-fluorothiazol-2-amine (III-4, Scheme 9).
[0460]
[0461] Solution 9
[0462] To a solution of 4-(3-chloro-4-fluorophenyl)-1,3-thiazol-2-ylamine (III-2, 1 g, 4.37 mmol, 1.0 eq) in MeCN (20 mL) at 0 °C under N2 was added 1-(chloromethyl)-4-fluoro-1,4-diazabicyclo[2.2.2]octane; ditetrafluoroborate (Selectfluor TM) (1.55 g, 4.37 mmol, 1.0 eq). The mixture was heated to 25 ° C and stirred for 6 hours. Thereafter, LC-MS showed that about 12% of the starting material remained. LC-MS showed several new peaks and detected about 22% of the desired compound (III-4). Water (30 mL) was added; and the reaction mixture was diluted with EtOAc (30 mL) and water (10 mL). The aqueous layer was extracted with EtOAc (2 x 20 mL). The combined organic phases were washed with water (2 x 15 mL) and brine (2 x 15 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (SiO2, PE / EtOAc=0 to 100% EA). 4-(3-chloro-4-fluorophenyl)-5-fluorothiazole-2-amine (III-4) (230 mg, 21% yield) was isolated as a brown solid and used in the next step without further purification. 1 H NMR (400MHz, DMSO-d6) δ7.79 (dd, J = 7.3, 2.1 Hz, 1H), 7.68 (ddd, J = 8.6, 4.7, 2.2 Hz, 1H), 7.48 (t, J = 9.0 Hz, 1H), 7.08 (s, 2H).
[0463] Preparation Example 7: Synthesis of 4-(3,4-difluorophenyl)-5-fluorothiazol-2-amine (III-5, Scheme 10).
[0464]
[0465] Solution 10
[0466] To a solution of 4-(3,4-difluorophenyl)-1,3-thiazol-2-amine (III-3, 12.7 g, 59.84 mmol, 1 eq) in DMF (150 mL) was added 1-(chloromethyl)-4-fluoro-1,4-diazabicyclo[2.2.2]octane; ditetrafluoroborate (Selectfluor TM ) (21.20 g, 59.84 mmol, 1 eq) and 2,6-lutidine (6.41 g, 59.84 mmol, 6.97 mL, 1 eq). The mixture was then stirred at 25 ° C for 10 hours, and LC-MS showed that the reaction was complete. The mixture was extracted with ethyl acetate (400 mL x 3). The combined organic layers were dried over Na2SO4 and filtered. The filtrate was evaporated to dryness to give a crude product, which was subjected to flash silica gel chromatography ( 80g Silica gel flash column, 22% to 25% ethyl acetate / petroleum ether gradient elution @80mL / min), petroleum ether / ethyl acetate = 3:1, Rf = 0.4) to obtain the product 4-(3,4-difluorophenyl)-5-fluorothiazol-2-amine, III-5 (8.9 g, 36.65 mmol, 61.2% yield, 94.8% purity) as a gray solid. LC-MS: (M+H) + =230.7; 1 H NMR (400MHz, DMSO-d6): 7.58 (br d, J=2.0Hz, 1H), 7.55-7.51 (m, 1H), 7.45 (s, 1H), 7.06 (s, 2H)
[0467] Preparation Example 8: Synthesis of 4-(4-chloro-3-fluorophenyl)-5-fluoro-1,3-thiazol-2-ylamine (III-6, Scheme 11).
[0468]
[0469] Solution 11
[0470] To a solution of 4-(4-chloro-3-fluorophenyl)thiazol-2-amine (III-1, 1 g, 4.37 mmol, 1.0 eq) in MeCN (15 mL) at 25 °C under N2 was added 1-(chloromethyl)-4-fluoro-1,4-diazabicyclo[2.2.2]octane; ditetrafluoroborate (Selectfluor TM ) (1.55 g, 4.37 mmol, 1.0 eq). The mixture was stirred at 25 ° C for 16 hours. LC-MS showed that about 11% of the starting material remained. LC-MS showed several new peaks and detected about 21% of the desired compound. The reaction mixture was diluted with EtOAc (30 mL) and water (20 mL). The aqueous layer was extracted with EtOAc (2 x 20 mL). The combined organic phases were washed with water (2 x 15 mL) and brine (2 x 15 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (SiO2, petroleum ether / EtOAc=0 to 100% EtOAc). The title compound (350 mg, 32% yield) was obtained as a brown solid.
[0471] Preparation Example 9: N-(6-(N-(4-(4-chloro-3-fluorophenyl)thiazol-2-yl)sulfamoyl)pyridin-3-yl)acetyl Synthesis of amine (IV-1).
[0472]
[0473] At 25 ° C, under N2, 5-acetylaminopyridine-2-sulfonyl chloride (II-1 2g, 8.52mmol, 1.95eq) was added to a solution of 4-(4-chloro-3-fluorophenyl)thiazole-2-amine (III-1) 1g, 4.37mmol, 1eq) in pyridine (5mL) at one time. The mixture was stirred at 25 ° C for 4 hours. LC-MS showed that compound II-1 was completely consumed and a main peak with the desired m / z was detected. The mixture was poured into 1M HCl (40mL) and stirred for 10min. The aqueous phase was filtered to obtain a crude product. The crude product can be used without further purification.
[0474] Preparation Example 10: N-(6-(N-(4-(3,4-difluorophenyl)-5-fluorothiazol-2-yl)sulfamoyl)-5-methylpyrrolidone Synthesis of 2-pyridin-3-yl)acetamide (IV-2).
[0475]
[0476] To a mixture of 5-acetylamino-3-methylpyridine-2-sulfonyl chloride (II-2, 2.9 g, 11.66 mmol) and 4-(3,4-difluorophenyl)-5-fluorothiazole-2-amine (III-5, 2.68 g, 11.66 mmol) in pyridine (15 mL) was degassed and purged with N2 3 times, and then the mixture was stirred at 25 ° C under N2 atmosphere for 16 hours. Thereafter, LC-MS showed that the reaction was complete. The reaction mixture was concentrated under reduced pressure to remove the solvent. The resulting residue was diluted with H2O (50 mL) and extracted with ethyl acetate (30 mL × 3). The combined organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to obtain a residue. The resulting crude product was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=100 / 0 to 20 / 80) to obtain compound IV-2 (3.47 g, 67.26% yield) as a brown solid. LC-MS: (M+H) + =443.0Da.
[0477] Preparation Example 11: Preparation of 5-amino-N-(4-(4-chloro-3-fluorophenyl)thiazol-2-yl)pyridine-2-sulfonamide (V-1) synthesis.
[0478]
[0479] To a solution of N-(6-(N-(4-chloro-3-fluorophenyl)thiazol-2-yl)sulfamoyl)pyridin-3-yl)acetamide (IV-1, 1.5 g, 3.51 mmol, 1 eq) in H2O (987 mg, 54.8 mmol, 988 μL, 15.6 eq) and EtOH (20 mL) was added NaOH (983 mg, 24.6 mmol, 7 eq) at 25 °C under N2. The mixture was heated to 90 °C and stirred for 1.5 hours. LC-MS showed that the starting material was completely consumed and one major peak with the desired mass was detected. The mixture was concentrated under reduced pressure. The residue was poured into water (10 mL), the pH of the mixture was adjusted to 7 with 1 M HCl, and then the residue was filtered to afford 5-amino-N-(4-(4-chloro-3-fluorophenyl)thiazol-2-yl)pyridine-2-sulfonamide (V-1) (1 g, 74% yield, yellow solid), which was used without further purification.
[0480] Preparation Example 12: 5-amino-N-(4-(3,4-difluorophenyl)-5-fluorothiazol-2-yl)-3-methylpyridine-2-sulfonyl Synthesis of amide (V-2).
[0481]
[0482] To a solution of N-(6-(N-(4-(3,4-difluorophenyl)-5-fluorothiazol-2-yl)sulfamoyl)-5-methylpyridin-3-yl)acetamide (IV-2, 4.64 g, 10.49 mmol) in ethanol (50 mL) and water (50 mL) was added sodium hydroxide (3.36 g, 83.90 mmol). The mixture was stirred at 80 ° C for 0.5 hours. Thereafter, LC-MS showed that the reaction was complete. The reaction mixture was extracted with ethyl acetate (500 mL x 3), washed with brine (120 mL x 2), dried over Na2SO4 and concentrated to give crude 5-amino-N-(4-(3,4-difluorophenyl)-5-fluorothiazol-2-yl)-3-methylpyridine-2-sulfonamide (V-2, 3.77 g, 90% yield) as a red oil. LC-MS: (M+H) + =400.9; 1 H NMR (400MHz, DMSO-d6): 7.64-7.54 (m, 2H), 7.54-7.47 (m, 1H), 7.47-7.37 (m, 1H), 6.72 (d, J = 2.0Hz, 1H), 5.60 (br s, 2H), 2.42 (s, 3H).
[0483] Preparation Example 13: N-(4-(4-chloro-3-fluorophenyl)thiazol-2-yl)-5-((2-hydroxy-3-methoxybenzylidene) Synthesis of amino)pyridine-2-sulfonamide (VII-1).
[0484]
[0485] At 25 ° C, under N2, to a mixture of 5-amino-N-(4-(4-chloro-3-fluorophenyl)thiazol-2-yl)pyridine-2-sulfonamide (V-1, 200 mg, 520 μmol, 1 eq) and 2-hydroxy-3-methoxybenzaldehyde (118.6 mg, 780 μmol, 1.5 eq.; Formula VI) in EtOH (5 mL) was added trifluoroacetic acid (59.3 mg, 519.7 μmol, 38.5 μL, 1 eq.) in one portion. The mixture was heated to 25 ° C and stirred for 7 hours. LC-MS showed that the starting amine was completely consumed. The mixture was cooled to 25 ° C and concentrated under reduced pressure. The crude product of N-(4-(4-chloro-3-fluorophenyl)thiazol-2-yl)-5-((2-hydroxy-3-methoxybenzylidene)amino)pyridine-2-sulfonamide (VII-1, 260 mg, 96% yield) was used in the next step without further purification.
[0486] Preparation Example 14: N-(4-(3,4-difluorophenyl)-5-fluorothiazol-2-yl)-5-((2-hydroxy-3-methoxybenzylidene) Synthesis of 2-(4-(2-methylpyridine)amino)-3-methylpyridine-2-sulfonamide (VII-2) .
[0487]
[0488] 5-amino-N-(4-(3,4-difluorophenyl)-5-fluorothiazol-2-yl)-3-methylpyridine-2-sulfonamide (V-2, 1g, 2.50mmol) is added to a toluene (10mL) solution of 2-hydroxy-3-methoxy-benzaldehyde (567mg, 3.75mmol). The mixture is stirred at 140 ° C for 2 hours. After that, LC-MS shows that the reaction is complete. The solvent is removed under reduced pressure to obtain crude N-(4-(3,4-difluorophenyl)-5-fluorothiazol-2-yl)-5-((2-hydroxy-3-methoxybenzylidene) amino)-3-methylpyridine-2-sulfonamide (VII-2, 1.2g, crude product), which is a brown solid.
[0489] Preparation of compounds of formula (I)
[0490] Preparation Example 15: N-(4-(4-chloro-3-fluorophenyl)thiazol-2-yl)-5-((2-hydroxy-3-methoxybenzyl)amino Synthesis of 2-(2-(2-(4-(2-pyridine)sulfonamide) (Compound I-8) .
[0491]
[0492] To a solution of N-(4-(4-chloro-3-fluorophenyl)thiazol-2-yl)-5-((2-hydroxy-3-methoxybenzylidene)amino)pyridine-2-sulfonamide (VII-1, 260 mg, 501 μmol, 1 eq) in DMF (5 mL) was added sodium triacetoxyborohydride (STAB, 425 mg, 2.00 mmol, 4 eq) at 25 °C under N2. The mixture was stirred at 25 °C for 16 hours. LC-MS showed complete consumption of the starting material and one major peak with the desired m / z was detected. The reaction mixture was poured into water (50 mL) and stirred for 10 min. The aqueous phase was filtered to give the crude product. The residue was purified by preparative HPLC (TFA conditions) to give N-(4-(4-chloro-3-fluorophenyl)thiazol-2-yl)-5-((2-hydroxy-3-methoxybenzyl)amino)pyridine-2-sulfonamide, 1-8, as a white solid (58.6 mg, 22% yield).
[0493] Preparation Example 16: N-(4-(3,4-difluorophenyl)-5-fluorothiazol-2-yl)-5-((2-hydroxy-3-methoxybenzyl)- Synthesis of 2-(2-methylpyridine-2-sulfonamide) (I-18) .
[0494] Compound 1-18 can be prepared according to Scheme 12:
[0495]
[0496] Solution 12
[0497] At 25 ° C, sodium triacetoxyborohydride (9.52 g, 44.90 mmol) was added to a solution of N-(4-(3,4-difluorophenyl)-5-fluorothiazol-2-yl)-5-((2-hydroxy-3-methoxybenzylidene)amino)-3-methylpyridine-2-sulfonamide (VII-2, 1.2 g, 2.24 mmol) in DCE (15 mL). The mixture was stirred at 25 ° C for 0.5 hours. After that, LC-MS showed that the reaction was complete. The reaction mixture was diluted with ethyl acetate (30 mL x 3), washed with brine (50 mL x 2), dried over Na2SO4 and concentrated to obtain a residue. The residue was purified by column chromatography (silica gel, 100-200 mesh, 60% ethyl acetate in petroleum ether) to give N-(4-(3,4-difluorophenyl)-5-fluorothiazol-2-yl)-5-((2-hydroxy-3-methoxybenzyl)amino)-3-methylpyridine-2-sulfonamide (I-18, 0.360 g, 29.9% yield) as a brown solid. LC-MS: (M+H) + =537.0; 1H NMR (400MHz, DMSO-d6): 8.82 (s, 1H), 7.76 (d, J = 2.3Hz, 1H), 7.70-7.63 (m, 1H), 7.61-7.54 (m, 1H), 7.53 (br d, J = 3.4Hz, 1H), 7.02 (br t,J=5.4Hz,1H),6.89-6.83(m,2H),6.79-6.69(m,2H),4.27(br d,J=5.8Hz,2H),3.79(s,3H),2.46(s,3H)
[0498] For example, DCE / MeOH and DCE / DMF can also be used instead of DCE to improve the solubility of the reagent.
[0499] The compounds in Table 1 were prepared in a manner apparent to one of ordinary skill in the art and by modification of the procedures and methods described herein.
[0500]
[0501]
[0502]
[0503]
[0504]
[0505]
[0506]
[0507]
[0508]
[0509]
[0510]
[0511]
[0512]
[0513]
[0514] In some embodiments, the present invention provides a compound as shown in Table 1 or a pharmaceutically acceptable salt thereof.
[0515] Compositions and preparations
[0516] Parenteral dosage forms.
[0517] In one embodiment, the novel compounds described herein can be administered in a parenteral dosage form. As used herein, the term "parenteral" includes, but is not limited to, subcutaneous injection, intravenous, intramuscular, intraperitoneal injection or infusion techniques. In one embodiment, the parenteral pharmaceutical formulations described herein comprise the compounds described herein and a pharmaceutically acceptable carrier. In one embodiment, the parenteral pharmaceutical formulations may contain a liquid carrier, including vegetable oils (such as peanut oil, cottonseed oil, sesame oil) and organic solvents (PEG, propylene glycol, glycerol) and surfactants. In certain embodiments for parenteral administration, the conjugates of the invention are mixed with a solubilizing agent, such as Cremophor. TM , alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers and mixtures thereof.
[0518] In another embodiment, the parenteral pharmaceutical formulation is aqueous. In one embodiment, the aqueous parenteral pharmaceutical formulation comprises at least 50% water, preferably 70% or more water. In another embodiment, the pharmaceutical carrier comprises a solubilizing agent. In a specific embodiment, the solubilizing agent is a 2-hydroxyalkylated β-cyclodextrin, such as hydroxyethyl β-CD, hydroxypropyl-β-CD, hydroxybutyl β-CD or sulfobutyl ether-β-cyclodextrin.
[0519] Pharmaceutically acceptable 2-hydroxyalkylated β-cyclodextrins may be present in any suitable amount in the aqueous parenteral pharmaceutical formulations described herein. Pharmaceutically acceptable 2-hydroxyalkylated β-cyclodextrins may be present in an amount of about 5% to 50% w / v. For example, a pharmaceutically acceptable solubilizer, optionally HP-β-CD, may be in an amount of about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45% or 50% w / v. In a specific embodiment, HP-β-CD may be present in an amount of about 10% to about 40%, about 20% to about 40%, about 30% to about 40%, about 10% to about 30%, or about 10% to about 20% of the total formulation. In one embodiment, 2-hydroxyalkylated β-cyclodextrins may be present in an amount of about 25% of the total formulation w / v.
[0520] For parenteral administration, sterile solutions and suspensions are required. When intravenous administration is required, isotonic preparations are used, which usually contain suitable preservatives. Pharmaceutical preparations can be administered parenterally via injection pharmaceutical preparations, which include compounds dissolved in an inert liquid carrier such as sterile water or other pharmaceutically acceptable diluents.
[0521] Pharmaceutical compositions or preparations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions, which may contain antioxidants, buffers, bacteriostats, and solutes that make the preparation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions that may contain suspending agents and thickening agents. The composition may be present in unit dose or multi-dose containers, sealed ampoules and vials, and may be stored under freeze-drying (lyophilization) conditions that require only the addition of a sterile liquid carrier (e.g., water for injection, saline, aqueous glucose solution (D5W), lactated Ringer's solution) immediately before use. Immediately before use. Temporary injection solutions and suspensions may be prepared from sterile powders, granules, and tablets of the aforementioned types.
[0522] Parenteral preparations may further include at least one any suitable auxiliary agent, including but not limited to diluents, crystallization inhibitors, tonicity agents, water structure forming agents or disruptors, polymers, ion pairing agents, stabilizers, buffers, salts, lipophilic solvents, preservatives, adjuvants, etc. Pharmaceutically acceptable auxiliary agents are preferred. Examples and methods for preparing such sterile solutions are well known in the art and can be found in well-known texts, such as but not limited to REMINGTON'S PHARMACEUTICAL SCIENCES (Adejare, ed., 123rd ed., Academic Press. (2020); Handbook of Pharmaceutical Excipients, 9th ed., Pharmaceutical Press (2020)). A pharmaceutically acceptable carrier suitable for the mode of administration, solubility and / or stability of the compound can be conventionally selected.
[0523] Pharmaceutical excipients and additives that can be used in the parenteral drug formulations described herein can also include, but are not limited to, proteins, peptides, amino acids, lipids, and carbohydrates (e.g., sugars, including monosaccharides, disaccharides, trisaccharides, tetrasaccharides, and oligosaccharides; derivatized sugars, such as sugar alcohols, aldonic acids, esterified sugars; and polysaccharides or sugar polymers), which can be present alone or in combination, alone or in combination, in the range of 1% to 99.99% by weight or volume. Exemplary protein excipients include serum albumins such as human serum albumin (HSA), recombinant human albumin (rHA), gelatin, and casein. Representative amino acid components that can also exert buffering capacity include alanine, glycine, arginine, betaine, histidine, glutamic acid, aspartic acid, cysteine, lysine, leucine, isoleucine, valine, methionine, phenylalanine, and aspartame.
[0524] Carbohydrate excipients suitable for use in the parenteral pharmaceutical formulations described herein include, but are not limited to, monosaccharides (such as dextrose, fructose, maltose, galactose, glucose, D-mannose and sorbose); disaccharides (such as lactose, sucrose, trehalose and cellobiose); polysaccharides (such as raffinose, melezitose, maltodextrin, dextran and starch); and sugar alcohols (such as mannitol, xylitol, maltitol, lactitol, xylitol, sorbitol (sorbitol) and inositol).
[0525] The pharmaceutical formulations containing the compounds described herein may also include a pH adjuster. The pH adjuster may be a base, optionally sodium hydroxide. The pH adjuster may also be an acid, optionally hydrochloric acid.
[0526] In one embodiment, the disclosure provides stable parenteral pharmaceutical preparations and preservative solutions and preparations containing preservatives, and multipurpose preservative preparations suitable for pharmaceutical or veterinary use, which include at least one compound disclosed herein in a pharmaceutically acceptable preparation. Pharmaceutical preparations according to the disclosure may optionally include at least one known preservative. Preservatives include but are not limited to phenol, meta-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, phenylmercuric nitrate, phenoxyethanol, formaldehyde, chlorobutanol, magnesium chloride (e.g., hexahydrate), alkyl parahydroxybenzoates (methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, butyl parahydroxybenzoate), benzalkonium chloride, benzethonium chloride, sodium dehydroacetate and thimerosal, or its mixture in an aqueous diluent. As known in the art, any suitable concentration or mixture can be used, such as 0.001% to 5%, or any range or value therein. Non-limiting examples include no preservatives, 0.1% to 2% m-cresol, 0.1% to 3% benzyl alcohol, 0.001% to 0.5% thimerosal, 0.001% to 2.0% phenol, 0.0005% to 1.0% alkyl parabens.
[0527] Other excipients, such as isotonic agents, buffers, antioxidants, preservative enhancers, may be optionally added. When used, the amount of the most commonly used tension regulator is in the range of 0.1% to 1% (w / v). Non-limiting examples of suitable tension regulators include sodium chloride, glycerol, boric acid, calcium chloride, dextrose and potassium chloride. The preparation may include a local anesthetic to reduce potential pain during injection. If necessary, a physiologically tolerated buffer may be added to provide improved pH control. Pharmaceutical preparations may cover a wide range of pH, such as about pH 4 to about pH 10, specifically, about pH 5 to about pH 9, and more specifically, about 7.0 to about 9.0. In one aspect, the preparations described herein have a pH between about 8.4 and about 8.7.
[0528] The methods for preparing the pharmaceutical preparations described herein are manufactured in a known manner, including conventional mixing, dissolving or lyophilizing methods. Thus, aqueous pharmaceutical preparations can be obtained by mixing the active compound with a solid excipient, optionally grinding the resulting mixture and processing the granular mixture, if desired or necessary, after adding suitable auxiliaries.
[0529] Oral dosage form.
[0530] Pharmaceutical preparations of the compounds described herein that can be used for oral administration can be in the form of tablets or capsules, and can be immediate release preparations or can be controlled release or sustained release preparations, which can contain pharmaceutically acceptable excipients, such as corn starch, mannitol, povidone, magnesium stearate, talc, cellulose, methylcellulose, carboxymethylcellulose and similar substances. Pharmaceutical compositions containing compounds and / or their salts can contain one or more pharmaceutically acceptable excipients known in the art. Preparations include oral films, orally disintegrating tablets, effervescent tablets and granules or beads, which can be sprinkled on food or mixed with liquids into slurries or poured directly into the mouth and rinsed.
[0531] Pharmaceutical compositions containing compounds, salts and hydrates thereof can be prepared by any method known in the pharmaceutical art. Generally, such preparation methods include the steps of associating the 12-LOX inhibitor or a pharmaceutically acceptable salt thereof with a carrier or excipient and / or one or more other auxiliary agents, and then, if necessary and / or desired, shaping and / or packaging the product into the desired single or multiple dose units.
[0532] Pharmaceutical compositions can be prepared, packaged and / or sold in bulk as a single unit dose and / or as multiple single unit doses. As used herein, a "unit dose" is a discrete amount of a pharmaceutical composition containing a predetermined amount of an active ingredient. The amount of the active ingredient is generally equal to the dose of the active ingredient administered to the subject and / or a convenient fraction of this dose, such as, for example, one-half or one-third of this dose.
[0533] The relative amounts of active ingredient, pharmaceutically acceptable excipient and / or any additional ingredients in the pharmaceutical compositions of the invention will vary, depending on the identity, size and / or condition of the subject being treated and further on the route by which the composition is to be administered. The combination used in the methods of the invention comprises between 0.001% and 100% (w / w) of active ingredient.
[0534] Pharmaceutically acceptable excipients used in the manufacture of the provided pharmaceutical compositions include inert diluents, dispersants and / or granulating agents, surfactants and / or emulsifiers, disintegrants, binders, preservatives, buffers, lubricants and / or oils. Excipients such as cocoa butter and suppository waxes, colorants, coating agents, sweeteners, flavoring agents, and fragrances may also be present in the compositions.
[0535] In certain embodiments, the pharmaceutical composition used in the method of the present invention may include a diluent. Exemplary diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate, lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, corn starch, powdered sugar, and mixtures thereof.
[0536] In certain embodiments, the pharmaceutical composition used in the method of the present invention can include a granulating agent and / or a dispersing agent. Exemplary granulating agents and / or dispersing agents include potato starch, corn starch, tapioca starch, sodium starch glycolate, clay, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponges, cation exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly (vinyl pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (cross-linked carboxymethyl cellulose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water-insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (VEEGUM), sodium lauryl sulfate, quaternary ammonium compounds and mixtures thereof.
[0537] In certain embodiments, the pharmaceutical composition used in the method of the present invention can include adhesives. Exemplary adhesives include starch (e.g., corn starch and starch paste), gelatin, sugar (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc.), natural gums and synthetic gums (e.g., gum arabic, sodium alginate, Irish moss extract, panwar gum, ghatti gum, mucus of Isapol husk, carboxymethyl cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, microcrystalline cellulose, cellulose acetate, poly (vinyl pyrrolidone), magnesium aluminum silicate (VEEGUM.RTM.) and larch arabogalactan), alginate, polyethylene oxide, polyethylene glycol, inorganic calcium salt, silicic acid, polymethacrylate, wax, water, alcohol and / or its mixture.
[0538] In certain embodiments, the pharmaceutical composition used in the method of the present invention may include a preservative. Exemplary preservatives include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, antiprotozoal preservatives, alcohol preservatives, acidic preservatives and other preservatives. In certain embodiments, the preservative is an antioxidant. In other embodiments, the preservative is a chelating agent.
[0539] In certain embodiments, the pharmaceutical composition used in the method of the present invention may comprise an antioxidant. Exemplary antioxidants include alpha tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium pyrosulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium pyrosulfite, and sodium sulfite.
[0540] In certain embodiments, the pharmaceutical composition used in the method of the present invention may include a chelating agent. Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA) and its salts and hydrates (e.g., sodium edetate, disodium edetate, trisodium edetate, calcium disodium edetate, dipotassium edetate, etc.), citric acid and its salts and hydrates (e.g., citric acid monohydrate), fumaric acid and its salts and hydrates, malic acid and its salts and hydrates, phosphoric acid and its salts and hydrates, and tartaric acid and its salts and hydrates. Exemplary antimicrobial preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethanol, glycerol, hexetidine, imidourea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.
[0541] In certain embodiments, the pharmaceutical composition may include a buffer and a 12-LOX inhibitor or a salt thereof. Exemplary buffers include citrate buffer, acetate buffer, phosphate buffer, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glucuronate, calcium glucoheptonate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propionic acid, calcium levulinate, valeric acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, disodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethanol, and mixtures thereof.
[0542] In certain embodiments, the pharmaceutical composition used in the method of the present invention may include a lubricant. Exemplary lubricants include magnesium stearate, calcium stearate, stearic acid, silicon dioxide, talc, malt, glyceryl behenate, hydrogenated vegetable oil, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, and mixtures thereof.
[0543] In other embodiments, the pharmaceutical composition containing the 12-LOX inhibitor or a salt thereof is administered as a liquid oral dosage form. Liquid dosage forms for oral and parenteral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage form may contain inert diluents commonly used in the art, such as, for example, water or ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide and other solvents, solubilizers and emulsifiers, oils (e.g., cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol and fatty acid esters of sorbitan and mixtures thereof. In addition to inert diluents, oral compositions may also include adjuvants such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents and aromatics. In certain embodiments for parenteral administration, the conjugate of the present invention is mixed with a solubilizer, such as Cremophor TM , alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers and mixtures thereof.
[0544] Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active ingredient is mixed with at least one inert, pharmaceutically acceptable excipient or carrier: such as sodium citrate or dicalcium phosphate and / or (a) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol and silicic acid, (b) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and acacia, (c) humectants, such as glycerol, (d) disintegrants, such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate, (e) solution retarding agents, such as paraffin, (f) absorption promoters, such as quaternary ammonium compounds, (g) wetting agents, such as, for example, cetyl alcohol and glyceryl monostearate, (h) absorbents, such as kaolin and bentonite, and (i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may include buffering agents.
[0545] Some oral compositions of the present invention relate to sustained or controlled release formulations. These can be, for example, diffusion-controlled products, dissolution-controlled products, erosion products, osmotic pump systems or ionic resin systems. Diffusion-controlled products contain a water-insoluble polymer that controls the flow of water and the subsequent outflow of dissolved drug from the dosage form. Dissolution-controlled products control the release by using a slowly dissolving polymer or by microencapsulation of the drug, i.e., using different consistencies to control the dissolution rate of the drug. Erosion products control the release of the drug by the erosion rate of the carrier matrix. Osmotic pump systems release the drug based on the continuous influx of water across a semipermeable membrane into a reservoir containing an osmotic agent. Ion exchange resins can be used to bind the drug so that when ingested, the release of the drug is determined by the ionic environment in the gastrointestinal tract.
[0546] Method of administration and dosage
[0547] Those of ordinary skill in the art will appreciate that the administration of a pharmaceutically effective amount of the pharmaceutical formulations described herein to a patient in need thereof can be determined empirically or by standards currently recognized in the medical field. It should be understood that when administered to a human patient, the total daily dosage of the medicament of the composition described herein will be determined by the attending physician within the scope of reasonable medical judgment. The specific therapeutically effective dosage level for any particular patient will depend on a variety of factors: the type and extent of the cellular response to be achieved; the activity of the specific medicament or composition used; the specific medicament or composition used; the patient's age, weight, general health, sex and diet; the time of administration, route of administration and excretion rate of the medicament; the duration of treatment; drugs used in combination or concomitantly with a specific medicament; and similar factors well known in the medical field. It is entirely within the technical scope of the art to start using the medicament at a dosage level lower than the dosage level required to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
[0548] Also disclosed are routes of administration and dosages of parenteral pharmaceutical formulations comprising an effective amount of a 12-LOX inhibitor compound. In one embodiment, administration is intravenous. The pharmaceutical compositions and / or formulations described herein may also be administered by infusion. The pharmaceutical formulations described herein may also be administered by bolus doses, optionally in combination with administration by infusion. The compounds described herein may be administered in combination with other agents in a variety of regimens to effectively treat a disease.
[0549] Parenteral pharmaceutical preparations can be administered in a single daily dose, or the total daily dose can be administered in divided doses twice, three times or four times a day. The dosage can be administered for a week, a month, or several months, 3, 6, 9 or 12 months, or known in the art and determined as a clinically relevant interval. In one embodiment, parenteral pharmaceutical preparations can be administered for a long time for several years or for a patient's lifetime. For example, pharmaceutical preparations as described herein can be administered for 7 days, 14 days, 21 days, 28 days or 35 days. The daily dose of the preparation can vary in a wide range of about 0.0001 to about 1,000 mg per patient per day, more specifically about 200 to about 700, preferably about 500 to 600 mg / days. For adults (about 60 kg), the range can be more particularly about 1 mg / kg to 100 mg / kg body weight per day, about 10 to 50 mg / kg, 20 to 60 mg / kg, preferably 10 to 20 mg / kg per day, or an equivalent dose determined by a practitioner, to reach a clinically relevant serum concentration.
[0550] Specifically, aqueous parenteral pharmaceutical formulations described herein can be administered at least once a day over the course of several weeks, months, or years. In one embodiment, the pharmaceutical formulation is administered at least once a day over several weeks to several months. In another embodiment, the pharmaceutical formulation is administered once a day over at least one year.
[0551] Aqueous parenteral drug formulations can be administered after using a local anesthetic, including but not limited to lidocaine, prilocaine, or a combination thereof. Ice or ethyl chloride spray can also be used before administration.
[0552] Sometimes it may be necessary to deliver the compounds described herein to a subject over an extended period of time, starting from a single administration for a period of one week to one year. Certain medical devices can be used to provide continuous intermittent or on-demand dosing to a patient. The device can be a pump for a diffuser, or other devices containing a drug reservoir and optional diagnostic or monitoring components to regulate the delivery of the drug. Various sustained-release dosage forms, storage tank dosage forms, or implant dosage forms can be used. These can be, for example, diffusion-controlled products, dissolution-controlled products, erosion products, osmotic pump systems, or ionic resin systems. Diffusion-controlled products contain a water-insoluble polymer that controls the flow of water and the subsequent outflow of dissolved drugs from the dosage form. Dissolution-controlled products control the dissolution rate of the drug by using a slowly dissolving polymer or by microencapsulation of the drug, i.e., using different consistencies to control release. Erosion products control the release of the drug by the erosion rate of the carrier matrix.
[0553] In one embodiment, the aqueous parenteral pharmaceutical formulations described herein can be administered by infusion. The infusion may include continuous infusion of about 1 to about 1000 mg of the novel compound in the aqueous pharmaceutical formulation. In another embodiment, the infusion is administered for 30 minutes to 23 hours.
[0554] The amount of compound infused may be about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 701 900, 910, 920, 930, 940, 950, 960, 970, 980, 990 or 1000 mg.
[0555] In one embodiment, the infusion can be continuous or repeated at intervals. In one embodiment, the interval is between about 1 day and 1 year, or between about 1 day and 6 months, or between 1 day and 1 month. In another embodiment, the infusion can be repeated in about 1 to 14 days, optionally in about 1 to 7 days. The infusion can be repeated in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 days. The infusion can be repeated between about 1 to 7 days, 3 to 8 days, 5 to 14 days, 9 to 14 days or 7 to 14 days.
[0556] For example, the pharmaceutical formulations described herein can be infused continuously or over a period of 1 to 23 hours (including all intervals therebetween) at a rate of about 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 260 mg, 270 mg (over 1 to 5 hours), 280 mg, 290 mg, 300 mg, 310 mg, 320 mg, 330 mg, 340 mg, 350 mg, 360 mg, 370 mg, 380 mg, 390 mg, 400 mg, 510 mg, 520 mg, 530 mg, 540 mg, 550 mg, 560 mg, 570 mg, 580 mg, 590 mg, 20mg, 530mg, 540mg, 550mg, 560mg, 570mg, 580mg, 590mg, 600mg, 610mg, 620mg, 630mg, 64 0mg, 650mg, 660mg, 670mg, 680mg, 690mg, 700mg, 710mg, 720mg, 730mg, 740mg, 750mg, 760m In one embodiment, the infusion is 1 to 12 hours, 1 to 6 hours, or 1 to 4 hours.
[0557] For oral dosage forms or preparations, the pharmaceutical composition can be applied in a single daily dose, or the total daily dose can be applied in divided doses twice, three times or four times a day. The dosage can be applied for a long time for a week, a month or several months, 3, 6, 9 or 12 months, or known in the art and determined as a clinically relevant interval. Administration can be continued throughout the patient's life cycle, or stopped when clinical judgment is needed. The daily dose of the composition can change in a wide range of about 0.0001 to about 1,000 mg per patient per day. For adults (body weight of about 60 kg), the range can be more specifically about 0.001 mg / kg to 10 mg / kg body weight per day, about 0.1 to 100 mg per day, about 1.0 to 50 mg or about 1.0 to 0 mg per day. In addition, the dosage can be about 0.5 to 10 mg / kg per day, about 1.0 to 5.0 mg / kg per day, 5.0 to 10 mg / kg per day or the equivalent dose determined by a practitioner, to achieve clinically relevant plasma / serum concentrations.
[0558] The aqueous pharmaceutical formulations described herein can be administered to any animal that can experience the beneficial effects of the compounds of the present invention, preferably to humans.
[0559] The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect.
[0560] Treatment and prevention methods
[0561] The novel 2-aminothiazole compounds and other compounds described herein can be used as selective 12-lipoxygenase (12-LOX) inhibitors and can be used to prevent or treat 12-LOX-mediated diseases. The present disclosure further provides methods for treating or preventing 12-LOX-mediated diseases or conditions, comprising administering to a mammal a therapeutically or prophylactically effective amount of a novel 2-aminothiazole derived compound or other compound described herein.
[0562] Lipoxygenases are involved in the first critical step of a series of metabolic pathways, and the products of these enzymes (eicosanoids) are precursors of hormones such as leukotrienes and lipoxins, which mediate a variety of cellular functions. (Serhan et al. Chem. Rev. 2011, 111, 5922-5943). Therefore, lipoxygenases and their bioactive metabolites (such as hydroxyeicosatetraenoic acid (HETE) and leukotriene A4) are associated with a variety of inflammatory diseases and cancer.
[0563] 12-LOX has been shown to play a role in many conditions and / or diseases, such as dermatological disorders and platelet hemostasis, transplantation / xenografts, cancer (including but not limited to prostate cancer, colorectal cancer, breast cancer, lung cancer and hematological diseases), type 1 and type 2 diabetes, diabetic nephropathy (diabetic nephropathy), diabetic neuropathy, diabetic retinopathy, cardiovascular disease (including but not limited to myocardial infarction, congestive heart failure, heart failure and stroke), thrombosis, heparin-induced thrombocytopenia (HIT), Alzheimer's disease, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, insulin resistance, arthritis, lupus (SLE), lupus nephritis and inflammation.
[0564] In one embodiment, the present invention provides a method for reducing U46619-induced, thrombin-induced, PAR1-AP, PAR4-AP-induced or collagen-induced platelet aggregation, comprising administering to a mammal a therapeutically or prophylactically effective amount of any compound, its salt, prodrug, enantiomer, enantiomer or diastereoisomer mixture.
[0565] In one embodiment, the present invention provides a method for reducing FcγRIIA-mediated platelet activation (e.g., activation induced by anti-CD9 or IV.3+GAM), comprising administering to a mammal a therapeutically or prophylactically effective amount of any compound, its salt, prodrug, enantiomer, enantiomer or diastereomeric mixture.
[0566] In certain embodiments, the disorder is an immune-mediated thrombocytopenia and a thrombotic disorder, including but not limited to thrombocytopenia associated with sepsis and heparin-induced thrombocytopenia (HIT).
[0567] In preferred embodiments, the disease or condition to be treated by the disclosed 12-LOX inhibitor compounds is selected from thrombosis, HIT, and type 1 and type 2 diabetes.
[0568] In specific embodiments, the disorder is heparin-induced thrombocytopenia (HIT).
[0569] In specific embodiments, the disorder is type 1 diabetes.
[0570] In one embodiment, the present invention provides a method for treating or preventing a disease or condition mediated by 12-lipoxygenase, comprising administering to a mammal a therapeutically or prophylactically effective amount of any compound or a salt, prodrug, enantiomer, enantiomer or diastereomeric mixture thereof.
[0571] Combination therapy
[0572] The pharmaceutical formulations described herein may further comprise additional therapeutic agents or combinations thereof.
[0573] Additional therapeutic agents may be other 12-LOX inhibitors. 12-LOX inhibitors may be organic compounds, inorganic compounds, biological compounds (e.g., proteins or fragments thereof, antibodies or fragments thereof, nucleic acids, nucleic acid analogs, carbohydrates or peptides), or any combination thereof. 12-LOX inhibitors may also be synthetic or naturally occurring. Selective 12-LOX inhibitors are described in U.S. Pat. Nos. 10,266,488 and 10,752,581.
[0574] The mixing ratio of the 12-LOX inhibitor can be optimized to provide the greatest therapeutic effect.
[0575] Additional agents include, but are not limited to, antithrombotic agents such as argatroban, fondaparinux, lepirudin, bivalirudin, danaparin and drotrecogen alfa; antidiabetic agents such as exenatide, albiglutide, pramlintide, semaglutide, lixisenatide and dulaglutide. Combinations with direct-acting oral coagulants are also contemplated, including but not limited to apixaban, dabigatran, rivaroxaban and edoxaban.
[0576] The present invention also contemplates co-administration of the aforementioned additional therapeutic agents in separate compositions or formulations simultaneously with, prior to, or after administration of the disclosed 12-LOX inhibitor compounds.
[0577] Biological Examples
[0578] The inhibition of some compounds against 12-LOX and selectivity were evaluated by measuring their inhibition of 15-LOX using a UV-Vis assay. Arachidonic acid (AA) was used as a substrate for 12-LOX and 15-LOX. ML355 was used as a control inhibitor for 12-LOX. ML351 (5-(methylamino)-2-(1-naphthyl)-4-cyano-oxazole) was used as a control inhibitor for 15-LOX.
[0579] The reaction buffer used for the lipoxygenase assay was as follows: 25 mM HEPES (pH 7.5) containing 0.01% Triton X-100. 1 mM 12-HPETE or 1 mM 15-HPETE stock solutions were prepared in 25 mM HEPES containing 0.01% Triton X-100.
[0580] A standard curve of 12-HPETE was prepared with serial dilutions of 0, 6.25, 12.5, 25, 50, 75 and 100 μM, and the final reaction volume in a 96-well clear flat-bottom UV-transparent microplate was 100 μL. The absorbance of 12-HPETE at each concentration was measured at 234 nm.
[0581] A standard curve of 15-HPETE was prepared with serial dilutions of 0, 3.125, 6.25, 12.5, 25, 50 and 100 μM, and the final reaction volume in a 96-well clear flat-bottom UV-transparent microplate was 100 μL. The absorbance of 12-HPETE at each concentration was measured at 234 nm.
[0582] The IC was obtained by determining the % inhibition at different inhibitor concentrations. 50 Value. IC 50 The final concentrations of control inhibitor and test compounds in the assay were determined to be 0, 0.03, 0.1, 0.3, 1, 3, 10 and 20 μM. The final concentration of DMSO in the assay was 0.05%.
[0583] 12-LOX IC 50 Sure. 12-LOX enzyme and AA were diluted to 120nM and 200μM, respectively, in HEPES buffer. 50μL of the test compound shown and 25μL of 120nM enzyme were preincubated at room temperature for 5min. The reaction was started by adding 25μL of 200μM AA. After a brief rotation (1000rpm, 15s), the reaction system was incubated for 5min. A blank control was set up by adding 25μL of HEPES to 50μL of control inhibitor compound (ML355) and 25μL of 200μM AA. The final concentrations of 12-LOX enzyme and AA were 30nM and 50μM, respectively. The absorbance of 12-HPETE at 234nm was measured.
[0584] 15-LOX IC 50 Sure. 15-LOX enzyme and AA were diluted to 480nM and 200μM, respectively, in HEPES buffer. 50μL of the test compound shown and 25μL of 480nM enzyme were pre-incubated at room temperature for 5min. The reaction was started by adding 25μL of 200μM AA. After a short rotation (1000rpm, 15s), the reaction system was incubated for 3min. A blank control was set by adding 25μL of HEPES to 50μL of control inhibitor compound (ML355) and 25μL of 200μM AA. The final concentrations of 15-LOX enzyme and AA were 120nM and 50μM, respectively. The absorbance of 15-HPETE at 234nm was measured. The assay was performed in duplicate.
[0585] IC was calculated using GraphPad Prism 8.0.2 50 value.
[0586] IC 50 Values were calculated using the residual activity (%) and the logarithm of the inhibitor concentration.
[0587] Remaining activity (%) = inhibitor OD value / excipient OD value × 100
[0588] IC of the compound 50 The values are shown in Table 2 below:
[0589] Table 2
[0590]
[0591]
[0592]
[0593] +++=<250nM
[0594] ++=250nM-1000nM
[0595] +=>1000nM
[0596] The foregoing merely summarizes certain aspects of the disclosure and is not intended, nor should it be construed, to limit the disclosure in any way.
[0597] Incorporated by Reference
[0598] The entire disclosure of each patent document and scientific article cited herein is incorporated by reference for all purposes. Equivalent.
[0599] The present disclosure may be implemented in other specific forms without departing from its spirit or essential characteristics. The foregoing embodiments should be considered illustrative in all categories rather than limiting the present invention described herein. The scope of the present disclosure is indicated by the appended claims rather than the foregoing description, and all changes within the meaning and scope equivalent to the claims are intended to be included therein.
Claims
1. A compound of formula (I): Where Z is And among them R1 is selected from hydrogen or optionally substituted cycloalkyl, aryl or C1-C3 alkylaryl, each of which is optionally substituted with one or more substituents independently selected from halogen, alkyl, haloalkyl, alkoxy, C1-C3 haloalkoxy or heterocycle; R2 is selected from H, halogen, deuterium, alkyl, haloalkyl, C1-C3 alkoxy and C1-C3 haloalkoxy, hydroxyalkyl, alkoxyalkyl, cycloalkyl including cyclopropyl, C1-C3 alkylaryl, or Substituted or unsubstituted aryl and aralkyl, or including Amides of, wherein R9 is independently selected from C1-C3 alkyl, cycloalkyl (including cyclopropyl) and substituted or unsubstituted phenyl; or R1 and R2 together with the thiazole ring form an optionally substituted 5-, 6- or 7-membered fused 1,2-carbocyclic ring system, wherein the ring carbons of the 5-, 6- or 7-membered fused ring are optionally substituted with one or more atoms selected from N, O and S. The fused 5-, 6- or 7-membered ring is optionally substituted independently with one or more halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, or an optionally substituted aromatic ring; Or R1 and R2 together with the carbon to which they are attached form a substituted or unsubstituted R3 is hydrogen, C1-C3 alkyl or C1-C3 haloalkyl; Each R4 is independently hydrogen, CD3, substituted or unsubstituted phenyl, cycloalkyl including cyclopropyl, C1-C3 alkyl, C1-C3 haloalkyl, -OR, C1-C3 haloalkoxy or halogen; R5 is hydrogen, C1-C3 alkyl or C1-C3 haloalkyl; R6 is hydrogen, CD3, alkyl, cycloalkyl, haloalkyl or Each R7 is independently hydrogen, alkyl, haloalkyl, cycloalkyl or halogen; R8 is hydrogen, alkyl, haloalkyl, cycloalkyl or halocycloalkyl; n is 0, 1 or 2; p is 0, 1, 2 or 3; or Its pharmaceutically acceptable salt, prodrug, solvate, hydrate or stereoisomer.
2. The compound according to claim 1, wherein the compound is of formula (I).
3. The compound according to claim 1, wherein R1 is phenyl substituted by two or more substituents independently selected from halogen, alkyl, haloalkyl, 3-F, 4-oxetanephenyl and C1-C3 haloalkoxy.
4. The compound according to any one of claims 1 to 3, wherein R1 is phenyl substituted by one or more halogens.
5. A compound according to any one of claims 1 to 4, wherein R1 is 6. The compound according to any one of claims 1 to 5, wherein R2 is hydrogen or deuterium.
7. A compound according to any one of claims 1 to 6, wherein R2 is halogen.
8. A compound according to any one of claims 1 to 7, wherein R2 is fluoro or chloro.
9. A compound according to any one of claims 1 to 5, wherein R2 is selected from substituted or unsubstituted aryl or aralkyl, hydroxyalkyl, cyclopropyl or amide.
10. A composition comprising the compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt, prodrug, solvate, hydrate or stereoisomer thereof, and a pharmaceutically acceptable carrier.
11. A method for treating or preventing a disease and / or condition mediated by 12-lipoxygenase, comprising administering to a subject a therapeutically effective amount of a compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate or stereoisomer thereof.
12. Compounds or a salt thereof, wherein R3, R4 and n are as defined in claim 1.
13. Compounds of formula (II): or a pharmaceutically acceptable salt thereof, wherein R3, R4 and n are as defined in claim 1.
14. Compounds according to formula IV or a salt thereof, wherein R1, R2, R4, R5 and n are as defined in claim 1.
15. A compound according to formula V: or a pharmaceutically acceptable salt thereof, wherein R1 to R5 and n are as defined in claim 1.
16. A compound of formula (VII) or (VIIa): or a pharmaceutically acceptable salt thereof, wherein R1 to R8, n and p are as defined in claim 1.
17. The compound according to claim 1, wherein R4 is methyl, fluorine or CF3.
18. The compound according to claim 4, wherein R4 is methyl, fluorine or CF3.
